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Hepatic cytochrome P450 (P450) mediated metabolism, which includes the metabolism of both
endogenous and exogenous chemicals, is an important process in the maintenance of
homeostasis and normal physiological function in humans. The expression and function of P450
genes are controlled by multiple regulatory factors and show great inter-individual differences.
Understating the underlying regulatory mechanisms to P450 genes is critical to evaluate the
metabolism capability and predict drug efficacy or toxicity. Long noncoding RNAs (lncRNAs)
are a class of recently discovered regulatory molecules in gene expression and function, which
are highly involved in multiple physiological activities across different species. Recent studies
also suggest that lncRNAs are involved in metabolism activities in humans. However, there is a
significant knowledge gap in understating how lncRNAs influences the expression and function
of P450 genes and downstream drug metabolism. The research project in this thesis mainly
focuses on understating the roles of two transcription factor neighborhood lncRNAs, HNF1αantisense-1 (HNF1α-AS1) and HNF4α-antisense-1 (HNF4α-AS1), in the regulation of P450
expression and P450 mediated drug metabolism. My results demonstrate that lncRNAs HNF1αAS1 and HNF4α-AS1 are able to regulate the expression of multiple P450 genes and P450
related transcription factors, including CAR and PXR. In addition, the manipulation of these
lncRNAs further impacted P450 mediated drug metabolism and toxicity. Taken together, these
studies indicate the critical regulatory roles of lncRNAs in drug metabolism through the
regulation of hepatic P450s. A better understanding of how lncRNAs impact drug usage in
clinical conditions is needed.
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Chapter 1. Introduction

1.1 Liver and drug metabolism
Liver is the major organ responsible for metabolism and biotransformation, which is critical
for the maintenance of homeostasis status in the human body. The substrates of liver metabolism
include both endogenous compounds, for example of glucose, lipids, and steroids, and exogenous
chemicals, such as environmental toxicants and drugs.
It has been reported that the majority of orally delivered pharmaceutical drugs will go through
liver mediated metabolism [1,2]. As most drug molecules are lipophilic in nature, it is difficult for
the drugs to be excreted from the human body in their native form directly. The overall aim of
drug metabolism is to transform the lipophilic drug compounds into a more hydrophilic form to
facilitate the excretion of the drugs from the human body through body fluids, such as urine and
bile.
Generally, the hepatic metabolism of the drugs is divided into two phases, Phase I metabolism
and Phase II metabolism. However, not all drugs will go through all these two phases to get
excreted. Some drugs might just undergo one phase and some drugs might be excreted directly
without being metabolized. Still, a majority of clinical used drugs go through Phase I and Phase II
metabolism sequentially before being excreted.
In Phase I metabolism, drugs will go through reactions including oxidation, reduction, and
hydrolysis. The purpose of these reactions is to add certain chemical groups to the drug molecules
and make them more water-soluble.
1

Oxidation is the most common reaction in Phase I metabolism, where a single oxygen atom is
added onto the drug molecules. Hepatic cytochrome P450s (P450) are the major mediators of
oxidation reactions in the liver. Examples of drugs undergoing oxidation metabolism include
acetaminophen (APAP), codeine, and omeprazole.
Reduction usually results in additions of hydrogen groups to drug molecules. Similar to the
oxidation reactions, reductions can also be catalyzed by P450s and often occur under anaerobic
conditions. An example drug undergoing reduction metabolism is warfarin, an anticoagulant drug
that is inactivated by metabolism.
Hydrolysis is also a Phase I reaction. However, P450s do not mediate this type of reactions.
The activities of the drugs can be altered in many different ways after being metabolized. For
most clinically used drugs, the metabolism leads to decreases in drug activity or causes drug
inactivation. For some drugs, including drugs termed as prodrugs, the metabolism can generate
active metabolites that have higher activities as compared to their parent drugs. Still, the activities
of some drugs do not change much after being metabolized.
Conjugation reactions are the major type of Phase II metabolism. By adding of ionized groups
to the drug molecules, conjugation reactions significantly increase the water solubility of drugs,
allowing drug excretion through urine and bile. Phase II metabolism reactions are mediated by a
group

of

conjugating

enzymes,

including

UDP-glucuronosyltransferases

(UGTs),

sulfotransferases (SULTs), N-acetyltransferases (NATs), and glutathione S-transferases (GSTs).
Unlike Phase I metabolism, Phase II metabolism usually results in the inactivation of drugs or the
active Phase I metabolites of drugs.

2

After the process of metabolism, lipophilic drug molecules generally transform into
hydrophilic metabolites and excrete through body fluids.

1.2 Cytochrome P450s enzymes
P450 enzymes are a group of oxidase enzymes, which are able to mediate reactions including
oxidation, sulfoxidation, aromatic hydroxylation, aliphatic hydroxylation, N-dealkylation, Odealkylation, and deamination [1]. P450s are involved in both exogenous detoxification and
endogenous biosynthesis or degradation processes.
P450 enzymes are expressed in a variety of living organisms, including humans, primates,
rodents, plants, bacteria, and fungi. In humans, more than 155 P450 genes and pseudogenes have
been annotated. The nomenclature system for P450s was developed by Nebert in the late 1980s.
The name of each individual P450 gene or enzyme consists of three parts, one family number, one
subfamily letter, and one identifying number. Human P450 members start with CYP1A1 and end
with CYP51P3 [3].
P450s are distributed in multiple organs and sites in the human body, including liver, kidney,
intestine, brain, and blood cells. At all these different sites, hepatic P450s contributes to the
majority of the metabolic function. Furthermore, the abundance of P450 members in the liver is
not equally distributed. In adult human livers, CYP3A4 is the most abundant P450 isoform,
followed by CYP2E1, 2C9, 1A2, 2A6, and 2C8 (Figure 1.1) [4]. Based on protein content, these
six P450 enzymes contribute to almost 80% of all hepatic P450 enzymes. However, the abundance
of P450 isoforms does not fully represent their metabolism capability regarding currently used
prescription drugs. Zanger and Schwab summarized the metabolic functions of P450s in a total
3

number of 248 clinical used drugs [5]. According to their results, CYP3A4 has the highest number
of substrate drugs, followed by CYP2D6, 2C9, and 2B6 (Figure 1.2).

4

Figure 1. 1 The abundances of P450 isoforms in human liver.
The abundance of hepatic P450 isoforms were measured and compared by mean protein value
(pmol protein/mg liver) in adult Caucasians (Data retrieved from [4]).

5

Figure 1. 2. Fraction of P450 isoforms in metabolizing clinically used drugs.
A total number of 248 clinical used drugs with known P450 mediated metabolism were
summarized and analyzed. Each metabolic pathway was counted only once for the major
contributing P450 isoform. (Data retrieved from [5])

6

1.3 Variabilities in cytochrome P450s
One major characteristic of P450s is the existence of significant variabilities. One study
comparing the Japanese and Caucasians hepatic microsomal P450s found that the contents for
several P450 isoforms were highly variable. Specifically, more than 50-fold variations were found
in CYP2A6, 2B6, and 2D6, a 20-fold variation in 1A2, a 12-fold variation in 2E1, and 5-fold
variation in 3A4 [6]. In another study focusing on the variation in CYP3A content found a 64-fold
variation in 20 donor livers, with a protein abundance range from 4 to 262 pmol/mg [7]. In addition
to the expression of P450 enzymes, variances can also be found in the P450 mediated drug
metabolic rate. A 31-fold variation was observed in the rate of testosterone 6β-hydroxylation
mediated by CYP3A4 [8]. A 100-fold variation was observed in the rate of dextromethorphan Odemethylation mediated by CYP2D6 [9]. In addition, a 40-fold variation was observed in the rate
of S-mephenytoin 4’-hydroxylation mediated by CYP2C9 [9].
In addition to the interindividual variations, the function and expression of P450s can also be
different within the same individual. It has been reported that age and health conditions also affect
the metabolic function of an individual, which are partially contributed by P450 dysregulation.

1.4 Regulatory factors in P450 expression and function
For drugs that undergoing P450 mediated metabolism, the variations in P450s will significantly
influence their therapeutic efficacy and toxicity in patients. Due to this, identifying the regulatory
factors that cause changes in P450 expression and functions is critical for a better understanding
of the mechanisms of P450 regulation and P450-associated guidance of clinical drug use.

7

Several well-established regulatory factors have been identified controlling the expression and
function of P450s, including genetic factors, epigenetic factors, and physiological factors. In this
section, these well-established regulatory factors will be discussed.

1.4.1 Genetic polymorphisms
As part of the pharmacogenetic study, the heritable changes on the genetic sequence of drugmetabolizing P450 genes and their effects on certain P450 isoforms and clinical relevance have
been studied for over sixty years [10]. Single nucleotide polymorphisms (SNPs) and copy number
variants (CNVs) are the two major polymorphisms identified in P450s genes, which cause either
enhanced or repressed enzymatic activities. It has been reported that most loss-of-function
polymorphisms in P450s genes happen at the level of mRNA splicing or expression, rather than
protein expression or structure [11]. The gain-of-function polymorphisms have multiple
mechanisms. The first type of gain-of-function polymorphisms is due to increased number of
functional gene copies (CNVs), this applies to CYP2D6, and CYP2A6 [12]. The second gain-offunction polymorphisms is increased substrate turnover due to variants in the promoter or amino
acid level, CYP2B6, 2C8, and 2C19 have been reported to be affected by this mechanism.
The type, frequency, functional effect, and clinical relevance of currently identified P450
polymorphisms have been summarized in several publications, which will not be discussed in
detail here [5,13-15].
The impacts of certain genetic polymorphisms on each P450 gene can vary significantly. Some
may lead to phenotype changes while others may not. Based on the phenotypes associated with
certain polymorphisms, the population could be divided into several groups: poor metabolizer,
8

intermediate metabolizer, extensive metabolizer, rapid metabolizer, and ultra-rapid metabolizer.
Among all these groups, extensive metabolizers refer to people with “normal” metabolic capability,
which also account for the majority of the population. When taking drugs, extensive metabolizers
will experience both therapeutic benefits and adverse effects. Intermediate metabolizers refer to
people with reduced P450 activity but still can metabolize a drug. Poor metabolizers have little to
no capability to metabolize usually due to polymorphisms causing loss-of-function in P450s.
Compared to extensive metabolizers, intermediate or poor metabolizers should be dosed with less
amount of drugs due to their limited metabolism capability. Intermediate or poor metabolizers may
experience more sever adverse effects because of slower clearance of a toxic drug. They may also
experience less therapeutic effect, when taking prodrugs, which need to be activated by
metabolism. Rapid and ultra-rapid metabolizers usually carry gain-of-function polymorphisms to
certain P450s, which give them a much greater capability to metabolize drugs. Dose adjustment
should also be considered when giving drugs to rapid and ultra-rapid metabolizers. For drugs
working in their parent form, higher doses will be needed to ensure the therapeutic effects, while
prodrugs may require lower doses to avoid excessive toxicity.
In clinical practice, based on the knowledge of how genetic polymorphisms affect P450mediated drug metabolism, the U.S. Food and Drug Administration has added special instructions
on several drugs to ensure the safety when being prescribed to patients carrying certain P450s
alleles. However, genetic polymorphisms were reported to account for less than 30% of the
interindividual variances in P450 expression and function, indicating the existence and importance
of other regulatory factors [16].

9

1.4.2 Epigenetic regulations
Epigenetics refers to the regulation of gene expression or phenotype, which does not cause
alterations in the DNA sequences. Comparing to genetic polymorphisms, epigenetic modifications
are mostly reversible and may be influenced by many factors such as age or disease. Mechanisms
involved in epigenetic regulation are DNA methylation, histone modifications, and noncoding
RNAs. There is increasing evidence showing that epigenetic alterations are highly involved in
P450 regulation and have great clinical implications [17].
DNA methylation refers to the process of adding methyl groups to the CpG islands with the
help of DNA methyltransferases. Hyper-methylated DNA sequences are usually associated with
gene repression, while hypo-methylated DNA sequences are associated with gene activation.
DNA methylation has been shown to regulate the expression of multiple P450 genes, including
CYP1A2, 2D6, and 2E1 [18]. Furthermore, DNA methylation has been shown to affect druginduced liver injury by regulating certain P450 enzymes [19,20].
Histone modifications are another common epigenetic mechanism in P450 regulation.
Depending on the types of added chemical groups, histone modifications can be further divided
into histone acetylation, which is mediated by histone acetyltransferases and deacetylases, and
histone methylation, which is mediated by histone methyltransferases and demethylases. Histone
modifications mainly affect the accessibility and transcriptional activity of the modified genes by
altering chromatin structures. Acetylation of histone tails usually leads to gene activation.
Knockdown of a histone deacetylase was reported to induce the expression of CPY2B10 in mouse
livers and CYP2B6 in HepG2 cells [21]. The effects of histone methylation on gene expression
are variable, depending on the modification sites and the number of added methyl groups. One
study showed that the transcriptional activity of CYP2C9 gene was regulated by the methylation
10

status of histone 3 lysine 27 (H3K27) tail, which affected the binding of HNF4α to the promoter
region of CYP2C9 gene [22]. H3K4 tri-methylation and H3K27 tri-methylation were also reported
to be important for rifampicin induced expression of CYP3A4 [23].
Recent studies also illuminated the impacts of noncoding RNAs (ncRNAs) on drug metabolism
and P450 expression. MicroRNAs (miRNAs) are small ncRNAs that have been shown to involve
in gene regulation through binding to target mRNAs. Several miRNAs have been identified to
regulate the expression of P450s. The regulation of P450s by miRNAs can work either directly or
indirectly. Examples of miRNAs that directly regulate P450s are miR-27b, which regulates
CYP1B1 and 3A4, and miR-378, which regulates CYP2E1 [24,25]. For indirect regulation,
miRNAs target P450 regulatory proteins, such as transcription factors, and influence P450
expression. Examples of miRNAs include miR-27b, which regulates vitamin D receptor and
peroxisome proliferator-activated receptor, and miR-613, which regulates liver X receptor [25,26].
Even though the field of P450 regulation by epigenetic mechanisms is still relatively new, there
are numerous examples demonstrating an important impacts of DNA methylation, histone
modifications, and ncRNAs in P450 regulation and clinical drug use.
1.4.3 Liver enriched transcription factors
Transcription factors are a class of proteins that control the transcription activity of target genes
through direct binding. Several liver-enriched transcription factors have been well-characterized
for their functions in the regulation of P450s [27]. Generally, P450 regulatory transcription factors
can be divided into two types: 1) ones that control the basal expression of P450s, and 2) ones that
control the induced expression of P450s. Hepatocyte nuclear factor 1α (HNF1α) and HNF4α are

11

well-characterized type 1 transcription factors, while pregnane X receptor (PXR) and constitutive
androstane receptor (CAR) are type 2 transcription factors (Figure 1.3).

Figure 1. 3. Transcription factors in P450 regulation.
(A) Diagram of general transcription factor function.
(B) Two types of transcription factor involved in P450 regulation.
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HNF1α is a homeodomain-containing transcription factor, which is expressed in several organs
including the liver, kidney, intestine, stomach, and pancreas. HNF1α has been reported to regulate
the transcription of several liver-specific genes involving in liver development, lipid metabolism,
and liver damage [28]. By combining gene studies and electrophoretic mobility shift studies, the
potential binding site of HNF1α has been identified in several P450 genes, including CYP2E1,
7A1, and 1A2 [29-31]. Using HNF1α deficient mice as an experimental model, Cheung et al. found
remarkable alterations of basal expression of several hepatic P450s. Specifically, the expression
of Cyp1a2, 2c29, 2e1, and 3a11 were reduced, while the expression of Cyp2a5, 2b10 and 2d9 were
elevated [32]. These results pointed out the critical roles of HNF1α in the regulation of P450s,
which might further impact drug metabolism and endogenous metabolism.
HNF4α is another transcription factor that is widely expressed in the human liver, kidney,
intestine, and pancreas. Previous studies have shown the implication of HNF4α in several
functions of the liver, including fatty acid metabolism, glucose metabolism, lipoprotein synthesis,
and liver differentiation [33-35]. HNF4α is able to bind to several motifs, including DR1 and HPF1 motifs. By using in vitro transfection assays in cultured cells, DR1 and HPF-1 motifs have been
found to be important for the activation of several P450 genes by HNF4α, including rabbit CYP2C1,
2C2, 2C3, human CYP2C9 and 2D6, rat CYP3A, and mouse CYP2D9 and CYP2A4 [36,37].
Knockdown of HNF4α in human hepatocytes using siRNA resulted in decreased basal mRNA
levels of CYP2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4, as well as PXR and CAR, indicating that
HNF4α plays a dominant role in the regulation of P450s and P450 related transcription factors in
human hepatocytes [38]. The majority of studies on HNF4α functions in P450 gene expression
were performed in vitro. Yet, in vivo studies are still needed given the fact that multiple regulatory
factors together contribute to the regulation of P450 expression in the liver.
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PXR and CAR are reported to regulate the drug-induced level of P450s in the liver. Upon
activation, both of them can form heterodimers with retinoid X receptor and bind to the response
element sequences on target P450 genes. Binding of the heterodimer to P450 genes leads to
transcription activation and up-regulation of P450 expression. Certain chemicals can serve as
ligands of PXR or CAR, and induce P450 expression, including clinically used drugs. Only certain
P450 isoforms can be induced by CAR and PXR. For example, members of the CYP2B, 2C, and
3A subfamilies can have both PXR and CAR dependent induction, while members of the CYP1A
subfamily can only be induced by CAR [39].
In addition to P450 regulation, transcription factors also regulate each other. PXR or CAR was
previously reported to show HNF4α dependent expression, and knockdown HNF4α decreased
mRNA levels of PXR and CAR, indicating the existence of a regulatory network in P450 and P450
regulatory transcription factors [38,40,41].

14

1.5 Non-coding genes and long non-coding RNAs (lncRNAs) in the genome
The advancement of next-generation sequencing techniques leads to a more detailed and
comprehensive investigation towards the genomes. It has been reported that the percentage of
protein coding genes in the genomes decreases with the increases in the complexity of an organism
(Figure 1.4) [42]. While the vast majority of the human genomes are transcribed into RNAs, around
98% of the generated transcripts do not have protein-coding functions and are regarded as ncRNAs
[43,44]. The genes coding for ncRNAs were once regarded as “junk” in the genomes. However,
recent studies have revealed biological significance with diverse functions in these ncRNA
transcripts. By definition, ncRNAs are transcripts that do not have protein coding capacity.
However, most ncRNAs can perform their functions directly as RNA molecules, including
structural, catalytic, and regulatory functions. Based on their functions, ncRNAs can be broadly
divided into two classes, the housekeeping ncRNAs and regulatory ncRNAs (Figure 1.5).
Examples of the housekeeping ncRNAs include the transfer RNAs (tRNAs), ribosomal RNAs
(rRNAs), small nuclear RNAs (snRNAs), and small nucleolar RNAs (snoRNAs). The roles of
these constitutively expressed housekeeping ncRNAs are involved in maintaining the normal
cellular behaviors and their functions have been well defined [45]. Regulatory ncRNAs are the
other type of ncRNAs widely existing across different species. Based on the length of the RNA
transcripts, regulatory ncRNAs can be further divided into short ncRNAs (less than 200 nt in length)
and long ncRNAs (lncRNAs) (more than 200 nt in length). Examples for short ncRNAs include
miRNAs and small interfering RNAs (siRNAs), whose functions are reviewed elsewhere and will
not be further discussed here [46,47].
The biosynthesis of lncRNAs is reported to be similar to messenger RNAs (mRNAs), which
are mediated by the RNA polymerase II. LncRNAs also have some of the distinctive features in
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the processes of biosynthesis, including polyadenylation, alternative splicing, and RNA cleavage,
which ultimately lead to isoforms of lncRNAs [48,49]. So far, more than 100,000 lncRNAs have
been annotated and reported in several databases in the human genome [50,51]. However, in
contrast to the achievements in identifying and mapping lncRNAs, the functional studies of
lncRNAs remains mostly elusive.
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Figure 1. 4. Noncoding genes in the genomes.
The percentage of protein-coding sequences (orange portions) in several eukaryotic and bacterial
genomes. Adopted from [42].
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Figure 1. 5. Classification of ncRNAs based on functional characteristics.
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The functions of lncRNAs are still questioned by several skepticisms. The major debate of
lncRNA function comes from the lack of strong sequence conservation of lncRNAs. During the
evolutionary selection, sequences or motifs with specific functions get selected and kept in
organisms. In this case, the level of sequence conservation has been used as an indicator of
functional significance to newly identified genes. RNA transcripts of coding genes, the mRNAs,
and especially the open reading frames of mRNAs, show a high level of conservation across
species [52]. This sequence conservation helps to prevent frameshift mutations and maintain the
normal function of coding genes. In comparison to mRNAs, lncRNAs showed only a moderate to
low level of sequence conservation, which supports the idea to consider lncRNAs as transcriptional
“noise” [53]. However, the idea of using sequence conservation to evaluate the functional
significance of lncRNAs was later challenged by several points. Firstly, a low sequence
conservation does not mean low function conservation. In fact, the lncRNAs might only need to
be conserved in a short region to keep their functions conserved. One example is the lncRNA Xist,
where it remained its function of X chromosome silencing in all eutherian females with a low
sequence conservation level [54,55]. Secondly, the promoter regions of lncRNAs have been
reported to show high conservation levels, which indicates that the transcription activity of
lncRNAs is highly conserved, regardless of the sequences of lncRNAs themselves [56]. Moreover,
the low conservation level might indicate higher evolutionary freedom in lncRNAs [57]. In
addition, the low abundance of lncRNAs in the genomes is another criticism in lncRNA functions.
The high-throughput sequencing techniques used for the detection of lncRNAs were able to detect
transcripts with very low abundance in the cells [58,59]. Whether these lncRNAs with low
abundance are functionally significant remains untested. The best way to address this question is
functional validation to each annotated lncRNAs.
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In contrast to these criticisms, several other features of lncRNAs also supported the idea that
lncRNAs are critical regulatory molecules in the genomes: 1) expression of lncRNAs changes
through development [60,61], 2) lncRNAs show tissue-specific expression [62,63], and 3)
lncRNAs are dysregulated in disease conditions [64,65].

1.6 Classification of lncRNAs
LncRNAs can be further classified based on their locations and orientations relative to coding
genes (Figure 1.6) [66]. Intergenic lncRNAs (lincRNAs) are lncRNAs that are located between
two coding genes. Intronic lncRNAs are lncRNAs that are positioned within the intronic region of
a coding gene. Sense lncRNAs are lncRNAs that are transcribed from the same strain of a coding
gene with sequence overlaps, while antisense lncRNAs are lncRNAs that are transcribed from the
opposite strain of a coding gene with sequence overlaps. Bidirectional lncRNAs are lncRNAs that
are transcribed from the opposite strain of a coding gene without sequence overlaps. However, this
classification is not comprehensive or complete since the discovery of new lncRNAs is still
ongoing. A more detailed classification of lncRNA subtypes or categories needs to be developed
in the coming future.
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Figure 1. 6. Classification of lncRNAs based on genomic locations.
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1.7 LncRNAs in gene regulation: functions and mechanisms
The “central dogma of molecular biology” describes the flow of genetic information, where
the genetic information coded by DNAs is transcribed into mRNAs and mRNAs are further
translated into proteins. LncRNAs have been reported to involve in nearly every step of gene
regulation (Figure 1.7).
In pre-transcriptional regulation, lncRNAs can turn the target gene on or off by affecting
chromatin structures through epigenetic modifications [67]. LncRNAs regulate histone codes in
two ways: 1) by directly interacting with chromatin-modifying complexes, and 2) by regulating
histone modification enzymes. LncRNA COLDAIR was reported to regulate the formation of
H3K27 histone markers by recruiting polycomb repressive complex 2 (PRC2), one histone
modification complex, to certain chromatin locations [68]. In another example, lncRNA
lncPRESS1 was reported to mediate histone acetylation by directly binding to a histone
deacetylase, SIRT6, and to cause inhibition of deacetylation on SIRT6 target genes [69].
LncRNAs are also involved in transcription regulation, which mainly occurs in the nucleus.
LncRNAs impact the process of transcription in multiple ways: 1) to directly bind with DNA
sequences and enhance or repress gene transcription, and 2) to interact with transcription related
proteins (transcription factors) and activate or inhibit downstream target gene transcription [70,71].
For example, lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has
been proven to interact with transcription factor specificity protein 1 in the activation of
transforming growth factor-β pathways in several cancers [72].
In the post-transcriptional process, lncRNAs are also highly involved. LncRNAs can affect the
processes of mRNAs and alter several features of mRNAs, such as splicing and stability [73].
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LncRNAs regulate splicing of mRNAs mainly through interacting with splicing factors, which are
critical in the determination of splicing sites. LncRNA MALAT1 was reported to interact with
serine/arginine-rich splicing factor 1 and facilitate the loading of splicing factors to nuclear
speckles. Further, knockdown of MALAT1 led to changes in splicing products of transcripts
[74,75]. LncRNA OCC-1 was reported to regulate the stability of Hu antigen R (HuR) targeted
mRNAs. HuR is an important stabilizing factor for a large number of mRNAs. By interacting with
both HuR and ubiquitin E3 ligase β-TrCP1, OOC-1 led to degradation of HuR by ubiquitination,
and thus destabilized HuR target mRNAs and downregulated them [76]. LncRNAs are also able
to interact with miRNAs to regulate their target mRNAs [77]. By interacting with miRNAs,
lncRNAs affect the stability of mRNAs, which are targeted by miRNAs.
LncRNAs, by acting as translational modulators, have been reported to regulate the translation
process in many ways. LncRNAs can modulate translational efficiency by recruiting translational
regulating proteins to the site of translation. LncRNA-p21 was reported to repress the translation
of β-catenin. By binding to β-catenin mRNAs, lncRNA-p21 enhanced the interaction between
mRNAs and translational repressors, including RCK and fragile X mental retardation protein,
ultimately leading to repressed translation of the target transcripts [78].

23

Figure 1. 7. LncRNAs in the central dogma of molecular biology.
LncRNAs have been found to involve nearly every level of gene expression. 1) In pretranscription, lncRNAs regulate gene expression by modifying histone markers or chromatin
structures. 2) In post-transcription, lncRNAs regulate several features of mRNAs including RNA
splicing or stability. 3) In translation, lncRNAs affect the efficiency of translation by recruiting
translational activators or repressors.
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The mechanisms of how lncRNAs regulate gene expression are complex and have not been
fully understood yet. Comparing to the identified amount of lncRNAs, there are far fewer lncRNAs
that have been functionally defined and assigned with explicit roles. Nevertheless, these lncRNAs
have shown their significance and importance in the regulation of gene expression [66,79]. Current
insights into the lncRNAs suggest that lncRNAs can interact with different biological molecules,
including RNAs [80,81], DNAs [80,82,83], and proteins [84,85] (Figure 1.8). The interaction with
DNAs and formation of lncRNA-DNA duplexes or triplexes are the basis of lncRNA in gene
regulation at the pre-transcriptional level. Examples of lncRNAs interacting with DNAs include
ANRASSF1 and ANRIL [86,87]. LncRNAs interacting with RNAs usually associate with gene
regulation at the post-transcriptional level, which modulates mRNA expression and functions.
Examples of lncRNAs, which are able to interact with RNA, include BACE1-AS1 and PTENpg1
[88-90]. LncRNAs interacting with proteins can perform diverse functions based on the protein
functions and are involved in all levels of gene regulation. LncRNA Xist, APOA1-AS, and
HOTAIR are example lncRNAs, which perform their functions through interacting with proteins
[91-93].
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Figure 1. 8. Examples of lncRNAs interacting with other biological molecules
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By interacting with other molecules, lncRNAs can perform their regulatory functions through
four defined molecular mechanisms: decoy, guide, scaffold, and signal (Figure 1.9) [94].
LncRNAs function as decoys, which can preclude the interaction between molecules, such as
DNA-protein interaction. Examples for this type of lncRNAs are Gas5 and PANDA [95,96].
LncRNAs functioning through guide and scaffold mechanisms share similar features. By binding
with multiple molecules and concentrating them in certain sub-cellular areas, the lncRNAs can
increase the interaction between these recruited molecules, including protein-protein interaction,
protein-DNA interaction, and protein-RNA interaction. One of the well-studied scaffold lncRNA
examples is HOTAIR, which can bind with two histone modification complexes, PRC2 and LSD1,
and involves in gene regulation by histone tail modification [97]. Signal lncRNAs are defined by
their function to activate or to repress genes or their ability to change the chromatin conformation.
Enhancer lncRNAs are reported to have this signal function in gene regulation, with lncRNA
HOTTIP as an example. HOTTIP was reported to directly interact with WDR5, a key component
protein in histone modification, inducing the formation of chromosome looping and enforcing gene
activation by maintaining histone H3K4me3 modification [98]. However, this archetype of
classification is oversimplified sometimes as one lncRNA may function through multiple
mechanisms. One example is the lncRNA Xist, which can regulate its target genes through both
signal and guide mechanisms [99,100].
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Figure 1. 9. Schematic diagram of mechanisms of lncRNAs.
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LncRNAs can act in both cis- and trans- manners, in terms of their functional modes (Figure
1.10) [101,102]. LncRNAs acting as cis-regulators are mainly involved in the expression and
function of their neighborhood coding genes, which are also likely to show expression correlation
with coding genes. Examples for cis-acting lncRNAs include lncRNA VIM-AS1 and CARMEN
[103,104]. On the other hand, trans-regulatory lncRNAs are involved in the regulation of distal
genes from their transcription sites, where lncRNA Firr is an example [105]. However, with the
progression in understanding lncRNA function, lncRNAs with both cis- and trans- regulatory
functions have been identified, where the lncRNA lncKdm2b is an example [106,107].
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Figure 1. 10. Schematic diagram of two modes in gene regulation by lncRNAs.
(A) LncRNAs functioning in a cis-regulation manner are more likely to regulate nearby coding
genes.
(B) LncRNAs functioning in a trans-regulation manner regulate distal genes from the site of
lncRNA transcription.
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1.8 Neighborhood antisense lncRNA
An antisense transcript refers to a transcript generated from the opposite transcription from the
opposite strand to a protein-coding or sense strand [108]. The existence of antisense transcription
is very common across different transcriptomes and these antisense transcripts are usually cotranscribed with their sense transcripts [109]. It has been demonstrated that more than 60% of the
sense transcripts have antisense partners [108,110]. LncRNAs have been identified to be one
common type of antisense transcripts of coding genes and involve in the regulation of function and
expression of their neighborhood coding genes.
There are several locations near a coding gene where antisense lncRNAs are likely to exist
(Figure 1.11). However, it is still not clear how different locations affect the function of lncRNAs.
Recent studies have found that these neighborhood lncRNAs might affect their nearby coding
genes in multiple ways, including regulation of the coding genes or involvement in the functional
regulation of the coding genes.
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Figure 1. 11. Locations of antisense neighborhood lncRNAs.
Depending on the relative location towards the coding gene, neighborhood lncRNAs are
categorized into several types: 1) Nearby to head, the 5’ end of the lncRNA is close to the 5’ end
of the coding gene; 2) Head to head, the 5’ end of both genes are aligned together; 3)
Overlapping, the antisense lncRNA overlaps with the sense coding gene; 4) Tail to tail, the 3’
end of both genes are aligned together; and 5) Nearby to tail, the 3’ end of the lncRNA is close to
the 3’ end of the coding gene.
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1.9 LncRNAs and transcription factors
Along with the advancements in the discovery of lncRNAs, there is an increasing amount of
studies trying to identify lncRNAs that have special relationships with coding genes. These
relationships include but not limit to correlations in expression, spatial localization, and function
[111-113].
There is increasing evidence showing that lncRNAs, including transcription factor
neighborhood antisense lncRNAs, are involved in the expression or functions of transcription
factors in gene regulation [114]. In this section, lncRNAs interacting with transcription factors are
summarized (Table 1.1).
LncSox4 is a lncRNA highly expressed in hepatocellular carcinoma (HCC) tissues and
epithelial ovarian cancer [115,116]. Chen and his colleagues found that the expression levels of
LncSox4 were correlated with the outcomes of HCC treatment, where patients with higher
LncSox4 expression usually had poorer outcomes. LncSox4 was found to be required for the selfrenewal of the tumor-initiating cells in HCC in a loss-of-function cell model. This effect of
LncSox4 was found to be related to its ability to interact with transcription factor signal transducer
and activator of transcription 3 (STAT3), a transcription factor that is previously reported to have
critical roles in cancer development and cell steaminess [117,118]. The binding of LncSox4 to
STAT3 resulted in the recruitment of STAT3 to the promoter region of the SOX4 gene and
transcription activation [115].
Lnc-DC is another lncRNA found to directly bind with transcription factor. Lnc-DC was found
to be exclusively expressed in conventional dendritic cells of the hematopoietic system [119].
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Table 1. 1. Examples of lncRNAs interacting with transcription factors.

LncRNA

Related TFs

Functions

Reference

LncSox4

STAT3

Initiate self-renewal of tumor-initiating cells

[115] [116]

in HCC.
Promote cell proliferation and inhibit
apoptosis in epithelial ovarian cancer.
Lnc-DC

STAT3

Mediate differentiation, development, and

[119]

function of dendritic cells.
GM10863

SOX10

Mediate synapse function through regulation

[120]

of Sox10 levels.
GATA3-AS1

GATA3

Involve in differentiation and function of T

[121]

helper 2 cells through GATA3, IL5, and
IL13 regulation.
GABPB1-AS1

GABPB1

Regulate cellular antioxidant capacity and

[122]

cell viability in HepG2 cells.
Linc-YY1

YY1

Promote myogenic differentiation and
muscle regeneration.
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[123]

Using both knockdown and overexpressed methods, Wang et al. found that lnc-DC was vital for
the differentiation process of dendritic cells. Further, they identified that lnc-DC was able to
directly bind with STAT3 and promote the phosphorylation of STAT3 by inhibition of the binding
of tyrosine phosphatase, SHP1, to phosphorylated STAT3. This mechanism of lnc-DC promots
the activation of STAT3 and downstream STAT3 dependent pathways in dendritic cell
differentiation, development, and function.
LncRNA GM10863 was identified in a search of lncRNA:mRNA pairs (mRNAs located
within 200 kb of the lncRNA gene body) using the UCSC genome browser performed by
Raveendra et al. [120]. In this project, GM10863 was identified to localize in the neighborhood
region of SOX10, which is a coding gene playing critical roles in the development and function of
neuro. The expression of GM10863 was found to correlate with the expression of SOX10 mRNA
in mouse primary hippocampal neurons. In addition, knockdown of GM10863 reduced the levels
of SOX10 mRNA and protein, indicating that GM10863 and SOX10 might work as a lncRNA:
transcription factor pair in terms of function [120].
GATA3-AS1 is a divergent lncRNA sharing a promoter region with transcription factor gene
GATA3, a master regulator in T helper 2 cell functions. In one study performed by Gibbons et al.,
GATA3-AS1 was found to control the expression of GATA3 as well as two interleukin genes, IL5
and IL13. Specifically, depletion of GATA3-AS1 resulted in a reduction in GATA3, IL5, and IL13
mRNA and protein levels, along with decreased T helper 2 cell polarization. This regulatory
function of GATA3-AS1 was accomplished through the interaction with histone-modifying
enzymes and the alteration of histone codes to its own gene locus, which is the shared promoter
region of GATA3 [121].
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GABPB1 is a transcription factor known to regulate the transcription of various genes related
to antioxidation process, including PRDX5 [124]. LncRNA GABPB1-AS1 is an antisense RNA
of GABPB1, which was previously reported to response to chemical-induced cellular stress [125].
A recent study showed that GABPB1-AS1 was able to affect the functions of GABPB1 by
modulating the translation process of GABPB1 in HepG2 cells, an in vitro model for HCC. The
up-regulation of GABPB1-AS1 inhibited the translation of GABPB1, which further reduced the
expression of peroxidase genes, including PRDX5, and accumulation of reactive oxygen species
and lipid peroxidation in the cells [122].
Yin Yang 1 (YY1) is an ubiquitously expressed transcription factor involved in the regulation
of cell proliferation and differentiation [126]. In muscle cells or myoblasts, YY1 regulates genes
involved in cell proliferation and differentiation by interacting with histone methyltransferase
complex and alterating of histone markers on target genes [127]. Linc-YY1 is a divergently
transcribed lncRNA located upstream of the mouse YY1-coding gene. The employment of lincYY1 loss- and gain-of-function assays in a mouse myoblast cell line showed that linc-YY1 was
important in the myogenic differentiation and muscle regeneration processes, and modulation of
linc-YY1 also affected YY1 target genes. This function of linc-YY1 was accomplished through
interacting with YY1 directly and eviction of YY1/Polycomb repressive complex, a complex
mediating histone methylation, from promoter regions of target genes [123].

1.10

LncRNAs in liver functions

Up to today, a number of lncRNAs have been found to impact the liver functions in many
aspects, both physiologically and pathologically [128]. As the major metabolic organ in the human
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body, the liver mediates the metabolism or detoxification of both endogenous and exogenous
materials every day. Liver dysfunction due to diseases will greatly impact the wellbeing of the
human body and life quality.
Previous studies mainly focus on the function of coding genes, including enzymes and
transporters, in the metabolic functions of the liver. Recent studies showed that lncRNAs were
also able to impact the development or metabolic activities of the liver. In this section, several
example lncRNAs known to affect liver functions are summarized and discussed.

1.10.1 LncRNAs in the liver development
The functions of the liver are not invariable during different stages of humans, nor does the
metabolic capability of the liver. The maturation of the liver is a process of the buildup of liver
functions during human development, which relies on the alteration of gene expressions.
Factors regulating the development or maturation of the liver might have direct effects on the
metabolic capability of the liver. Recent studies find that lncRNAs also have specific expression
patterns during different stages of liver development, which is similar to coding genes [129].
However, little is known about how lncRNAs are regulated during liver development or maturation
and few lncRNAs have been identified to directly involve in this process.
Using RNA sequencing techniques, one recent study observed dynamic transcriptional pattern
changes of lncRNAs during the postnatal development of mouse liver [129]. More than one
thousand hepatic lncRNAs showed differential expression levels during postnatal liver maturation.
Furthermore, three major oncogenic expression patterns of lncRNA during liver development were
identified, indicating that lncRNAs are involved in liver development. Another study examined
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lncRNA expression patterns in mouse embryonic liver and adult liver and showed similar results,
where the expression of lncRNAs followed specific patterns during liver development [130].

1.10.2 LncRNAs in the endogenous metabolism
The liver plays a critical role in the maintenance of metabolic homeostasis in humans [131].
This function relays on the abilities of the liver to synthesize, transform, store, and distribute
molecules including lipid and glucose. Several hepatic lncRNAs have been identified function as
regulatory factors of lipid or glucose levels through interference with liver functions.
LncLSTR is a livre enriched lncRNA, whose expression level alters along with changes in
energy levels and metabolic states. Knockdown of lncLSTR led to decreased plasma triglyceride
level in mice due to a higher triglyceride clearance rate. Mechanistically, lncLSTR upregulated
expression of CYP8B1 by interacting with TDP43 and disinhibiting the transcription of CYP8B1.
The increased level of CYP8B1 further impacted bile acid composition and activated FXR and
ApoC2 expression, which was involved in triglyceride clearance [132].
LncRNA lncARSR was reported to be reduced in non-alcoholic fatty liver disease (NAFLD)
patients and a mouse model with NAFLD, a common type of human chronic liver disease
characterized by the existence of hepatic steatosis (lipid accumulation) in patients without
excessive alcohol consumption or fatty liver. Hepatic lipid accumulation was enhanced by
overexpression of lncARSR while ameliorated by lncARSR knockdown, indicating that lncARSR
involved in lipid metabolism. A mechanistic study showed that lncARSR was able to regulate the
hepatic lipogenesis process via regulating SREBP-1c, a master regulator in lipogenesis [133].
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Lnc-HC was identified to be upregulated in the high-fat diet fed rat livers. Expression of lncHC was showed to negatively regulate cholesterol metabolism by regulating CYP7A1 and ABCA1,
which were important in bile acid synthesis and cholesterol efflux. Lnc-HC firstly bound with
partner molecular hnRNPA2B1. Then the lnc-HC/hnRNPA2B1 complex directly bound to
CYP7A1 and ABCA1 mRNAs and repressed their expression [134].
LncRNA SRA was reported to have a potential role in the adipogenesis process by regulating
PPARγ pathway and P38/JNK phosphorylation in adipocytes [135]. A recent study showed that
SRA was able to negatively regulate the expression of adipose triglyceride lipase (ATGL), a major
hepatic triacylglycerol hydrolase in mouse liver. Forced expression SRA in hepatocytes also led
to inhibition of ATGL expression along with the decreased activity of β-oxidation of free fatty
acids. In this way, SRA might promote the progression of hepatic steatosis by regulation of liver
metabolic activities [136].
LncRNA HULC is first identified as a cancer-related lncRNA, which is overexpressed in HCC
[137]. A later study found that HULC was able to regulate one miRNA miR-9, through alteration
in the methylation status of miR-9 promoter region. This HULC mediated miR-9 downregulation
further impacted the expression and functions of downstream miR-9 target genes, which were
involved in lipogenesis, and resulted in the accumulation of triglycerides and cholesterol [138].
APOA1-AS1 is an antisense lncRNA of APOA1 gene. APOA1, which is primarily synthesized
in the liver, is a major component of high-density lipoprotein in plasma. APOAl is also important
for reverse cholesterol transport and efflux of cholesterol from tissues [139]. The level of highdensity lipoprotein is closely related to the susceptibility of several cardiovascular diseases in
humans. APOA1-AS1 was found to negatively regulate the expression of the APOA1 both in vitro
and in vivo through affecting the histone markers of the APOA1 gene [92].
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Glucose is another important molecule in energy metabolism whose level also needs to be
tightly controlled. The liver mediates glucose level by a balanced system consisted of glucose
uptake, glucose storage, glycogenolysis, and gluconeogenesis. Recent studies found that several
lncRNAs were involved in the hepatic glucose metabolism by regulating coding genes in this
process.
Expression of lncRNA lncSHGL was found to be reduced in obese mouse livers, and its human
homolog lncRNA B4GALT1-AS1 was also found to be reduced in human livers with steatosis.
By overexpressing and knockdown of lncSHGL in mice, Wang et al. found that lncSHGL was
able to affect the process of gluconeogenesis [140]. Specifically, lncSHGL overexpression was
associated with suppressed gluconeogenesis in high-fat diet mice, whereas lncSHGL knockdown
was associated with promoted hyperglycemia in normal mice. Mechanistically, lncSHGL
enhanced the translation of calmodulin mRNA, a regulatory factor in gluconeogenic and lipogenic
pathways, by recruitment of heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) [140].
Hepatic glucokinase is an important regulatory factor mediating the transformation of the liver
from a glucose-consuming to a gluconeogenic organ under fasting conditions. LncRNA lncLGR
was found to downregulate the expression of glucokinase through transcription suppression, and
further impacted reduces hepatic glycogen content in vivo [141].
Expression of lncRNA Gm10768 was reported to be positively correlated with the glucose
production in mouse primary hepatocytes, indicating a potential role of Gm10768 in hepatic
gluconeogenesis. Overexpression of Gm10768 resulted in the activation of hepatic
gluconeogenesis in a cell autonomous manner and depletion of Gm10768 suppressed hepatic
glucose production. Mechanistically, Gm10768 sequestrated miRNA miR-214 from its target
genes and dis-inhibit transcription factor 4, a positive regulator of hepatic gluconeogenesis [142].
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Transcription factor MAFG is identified as a regulatory factor in hepatic energy metabolism
[143]. One recent study found that MAFG performed this function through a set of obesityassociated hepatic lncRNAs. LncIRS2 is one of these identified lncRNAs which was controlled by
MAFG and repressed under obese conditions. Depletion of LincIRS2 altered glucose metabolism
shown as elevated blood glucose level, insulin resistance, and aberrant glucose output [144]. These
results defined a novel coding gene-lncRNA axis in controlling hepatic glucose metabolism.

1.10.3 LncRNAs in liver diseases
LncRNAs have also been found to have critical functions in several kinds of liver diseases,
including fatty liver disease, liver fibrosis, and liver cancer [145-149]. Different roles of lncRNAs
in these diseases have been identified.
LncRNAs have the potential to work as biomarkers for disease diagnosis. LncRNAs were
found to be differentially expressed in health liver comparing to the diseased liver, including
NASH, NAFLD, liver fibrosis, and HCC. LncRNA APTR was identified to have the functions of
cell cycle and proliferation [150]. Expression of APRT was found to be higher in fibrotic livers of
mice and humans, where knockdown of APRT attenuated liver fibrosis in CCl4-treated mouse
livers [151]. Serum levels of APTR were also found to be higher in individuals with cirrhotic livers
of undisclosed etiology comparing to healthy livers, or in patients with decompensated cirrhosis
comparing to compensated cirrhosis, indicating that APTR may serve as biomarkers for liver
fibrosis. The plasma levels of lncRNA XLOC_014172 and LOC149086 were found to correlate
with tumorigenesis and metastasis in HCC, indicating that these two lncRNAs may serve as
biomarkers for HCC diagnosis or metastasis markers [152].
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Recent studies also found that lncRNAs have potential roles in regulating drug treatment
outcomes by modulation of cellular functions, including apoptosis, DNA repair, or drug processing,
including drug metabolism and transport [153]. Tsang et al. found that knockdown of lncRNA
H19 suppressed the mRNA expression of MDR1 and P-gp, which are well-known drug efflux
transporters. This inhibition of drug efflux transporters also increased the sensitivity of HCC cells
to doxorubicin treatment [154]. LncRNA TUG1 was reported to have similar effects regarding the
regulation of drug efflux transporter genes and drug efficacy [155].
In summary, there is increasing evidence showing that lncRNAs are highly involved in liver
physiology and functions. However, one major function of the liver is to metabolize exogenous
chemicals, such as drugs. There is still a huge knowledge gap regarding whether lncRNAs are
involved in liver mediated drug metabolism. Studies are urgently needed to address this question
and fill in the knowledge gap.
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Table 1. 2 LncRNAs involved in metabolic function of liver.

Liver function

LncRNA

LncRNA function

Reference

Lipid metabolism

lncLSTR

Enhance triglyceride

[132]

clearance and decrease
circulating triglyceride level.
lncARSR

Enhance hepatic lipogenesis.

[133]

lnc-HC

Repress cholesterol

[134]

metabolism.
SRA

Repress genes involved in

[136]

triacylglycerol hydrolase and
activity of β-oxidation of
free fatty acids.
HULC

Promote lipogenesis and

[138]

stimulate the accumulation
of intracellular triglycerides
and cholesterol
APOA1-AS1

Regulate the generation of
high-density lipoprotein
(APOA1).
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[92]

Glucose and lipid

LncSHGL

metabolism

Suppress both hepatic

[140]

gluconeogenesis and
lipogenesis.

Glucose metabolism

LncLGR

Reduce hepatic glycogen

[141]

storage by transcriptional
repression of glucokinase
expression.
Gm10768

Promote gluconeogenesis in

[142]

mouse liver.
LincIRS2

Knockdown of LincIRS2
caused elevated glucose
level in mice.
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[144]

1.11

LncRNA HNF1α-AS1 and HNF4α-AS1

1.11.1 Genomic locations and structures of HNF1α-AS1 and HNF4α-AS1
HNF1α-AS1, a neighbor antisense lncRNA gene of the human HNF1α gene, is located at
human Chromosome 12 with a length of 39.04 kb, containing 2 exons and 1 intron. The coding
gene HNF1α and noncoding gene HNF1α-AS1 formed a typical transcription factor-lncRNA pair
(Figure 1.12A). The coding potential of HNF1α-AS1 was analyzed by the Coding Potential
Calculator (http://cpc2.cbi.pku.edu.cn) [156]. The testing results suggest that HNF1α-AS1 is a
non-coding transcript (Figure 1.13A).
HNF4α-AS1, a neighbor antisense lncRNA gene of the human HNF4α gene, is located at
human Chromosome 20 with a length of 17.96 kb, containing 4 exons and 3 introns. The HNF4α
and HNF4α-AS1 genes also form a typical pair of coding and neighborhood antisense non-coding
genes (Figure 1.12B). Coding potential analysis also confirms the noncoding nature of HNF4αAS1 (Figure 1.13B).
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Figure 1. 12. Genomic locations of HNF1α, HNF1α-AS1, HNF4α, and HNF4α-AS1.
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Figure 1. 13. Coding potential analysis for HNF1α-AS1 and HNF4α-AS1.
Data is retrieved from Coding Potential Calculator (http://cpc2.cbi.pku.edu.cn), accessed on
3/16/2020.
The result for HNF1α-AS1 analysis is available at :
http://cpc2.cbi.pku.edu.cn/run_cpc2_result.php?userid=200317082945537

The result for HNF4α-AS1 analysis is available at :
http://cpc2.cbi.pku.edu.cn/run_cpc2_result.php?userid=200317498681153
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As mentioned above, HNF1α and HNF4α are well-studied transcription factors, controlling the
expression of numerous liver-specific genes. A specific tissue distribution pattern of HNF1α
mRNA was retrieved from the RNA-Seq Expression Data GTEx in 53 tissues from 570 donors
and showed relatively higher expression levels in the stomach, small intestine, colon, liver,
pancreas, and kidney, the major organs in the gastrointestinal (GI) tract (Figure 1.14A) [157]. A
similar pattern in the GI tract organs was also found for HNF1α-AS1 (Figure 1.14A), indicating
that HNF1α-AS1 is expressed in the organs where HNF1α is expressed. These results may suggest
that HNF1α-AS1 is possibly involved in the regulatory function of HNF1α in the GI tract organs.
Similar tissue distribution patterns are also found between HNF4α and HNF4α-AS1 in the GI tract
organs (Figure 1.14B). These similarities in tissue distribution might suggest functional
connections between the transcription factors and their neighborhood lncRNAs.
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Figure 1. 14. Tissue expression patterns of HNF1α, HNF1α-AS1, HNF4α, and HNF4α-AS1
(A) Tissue expression patterns of HNF1α and HNF1α-AS1. (B) Tissue expression patterns of
HNF4α

and

HNF4α-AS1.

Data

are

retrieved

(https://www.gtexportal.org/home/), accessed on 3/16/2020.
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from

GTEx

database

In addition to the chromatin locations, the structures of lncRNAs are also important for their
function and mechanism of action. RNA molecules have been shown to adopt higher-order tertiary
interactions [158]. Even though the relationships between lncRNA structure and functions are still
not fully understood yet, identification of structural domains, which mediate the interactions
between lncRNAs and other molecules, is critical for the characterization of lncRNA functions.
The secondary structures of HNF1α-AS1 was predicated using RNAfold program
(http://rna.tbi.univie.ac.at//cgi-bin/RNAWebSuite/RNAfold.cgi). The secondary structure of
HNF4α-AS1 was not predicated as the sequence length of HNF1α-AS1 exceeds the upper limit of
lncRNA FASTA input for the program.
As shown in Figure 1.15, HNF1α-AS1 is able to form a stable secondary structure based on
minimum free energy calculation. Several domains are also observed on the secondary structure
of HNF1α-AS1. However, it is still not very clear what molecules interact with these domains and
how they impact the functions of HNF1α-AS1 are still largely unknown.
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Figure 1. 15. Predication of HNF1α-AS1 secondary structure by RNAfold.
(A) Minimum free energy structure of HNF1α-AS1.
(B) Mountain plot representation of the MFE structure, the thermodynamic ensemble of RNA
structures, and the centroid structure. The positional entropy for each position is presented at the
bottom.
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1.11.2 Current understanding in HNF1α-AS1 and HNF4α-AS1 functions
Several functions of HNF1α-AS1 and HNF4α-AS1 have been reported in publications. In this
section, the identified functions of HNF1α-AS1 and HNF4α-AS1 will be summarized and
discussed.
Currently, a number of studies have shown that HNF1α-AS1 is actively involved in different
stages of cancer, including tumorigenesis, progression, and treatment. Significantly differentially
expressed HNF1α-AS1 has been found in several types of cancer tissues comparing to normal
tissues. However, the regulation patterns are different. Specifically, HNF1α-AS1 was upregulated
in esophageal, lung, bladder and colon cancers, and downregulated in gastric and pancreatic
cancers [159-164]. These controversial results indicated that HNF1α-AS1 might have tissuespecific functions. Most studies showed that the high expression levels of HNF1α-AS1 were
associated with a poor prognosis, a higher risk of metastasis, and a lower overall survival rate in
cancers [160,163,165-167].
HNF1α-AS1 plays a contradictory role in the development of cancer. Based on the cancer type,
HNF1α-AS1 was reported to function as either oncogene or tumor-suppressing gene. Zhang et al.
reported that HNF1α-AS1 promoted carcinogenesis in colorectal cancer by activating Wnt/βcatenin signaling pathway, indicating that HNF1α-AS1 might be used as a prognostic biomarker
in colorectal cancer [168]. In HCC, HNF1α-AS1was reported in one study to work as a tumor
repressor by decreasing tumor growth and metastasis [169]. However, two other studies focusing
on the roles of HNF1α-AS1 in HCC defined HNF1α-AS1 as an oncogene based on its function to
promote cell proliferation and hepatocarcinogenesis [167,170].
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For the progression of cancer, HNF1α-AS1 mainly regulates tumor growth and metastasis.
Knockdown of HNF1α-AS1 was reported to reduce cell proliferation rate in several in vitro cancer
cell lines, which might further affect tumor growth [166,171,172]. Metastasis is another major
activity during cancer progression. HNF1α-AS1 was also reported to involve in cancer metastasis
by regulating cell migration, invasion, colony formation, and epithelial-mesenchymal transition
(EMT), and knockdown of HNF1α-AS1 resulted in decreased cell movement or invasion, which
might further impact the metastasis of tumor [163,166,171-174].
Drug resistance is the major cause of treatment failure in cancer treatment. Several mechanisms
have been identified to contribute to the development of drug resistance in cancer cells, including
promoted cell survival and altered drug metabolism [175]. The expression of HNF1α-AS1 was
reported to affect the sensitivity of cancer cells to anti-cancer drugs. Cisplatin is a widely used
chemotherapeutic drug for the treatment of cervical cancer. In one study performed by Luo et al.,
knockdown of HNF1α-AS1 in cisplatin-resistant HeLa re-sensitized the cells to cisplatin treatment,
indicating that HNF1α-AS1 was involved in the regulation of drug resistance in cancer cells [176].
In summary, based on the findings in the current published articles, HNF1α-AS1 is an
important regulatory molecule in cancer biology. However, controversy still exists in the roles of
HNF1α-AS1 in cancers, and future studies are needed to clarify the functions of HNF1α-AS1.
In terms of HNF4α-AS1, the functional study is still very limited. HNF4α-AS1 was found to
be differentially expressed in HCC compared with adjacent cirrhotic tissues using RNA
sequencing techniques, indicating that HNF4α-AS1 may function as a biomarker for the
development of HCC in patients with cirrhosis [177]. Using co-expression and functional
annotation enrichment analyses across several tissues and cell types, Haberman and his colleagues
reported that HNF4α-AS1 was significantly down-regulated in patients with Crohn's disease,
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where the expression of HNF4α-AS1 also showed association with an epithelial metabolic
signature, indicating that HNF4α-AS1 might be a novel inflammatory signal or therapeutic target
for Crohn's disease [178].

1.11.3 Regulatory factors HNF1α-AS1 and HNF4α-AS1
The knowledge regarding how the expression of HNF1α-AS1 and HNF4α-AS1 get regulated
in cells is still very limited. According to literatures, these lncRNAs are can be regulated by their
neighborhood genes coded proteins, which are HNF1α and HNF4α.
One study identified HNF1α-AS1 as an HNF1α regulated lncRNA by comparing lncRNA
expressions in HNF1α overexpressed and knockdown Huh-7 cells. This result was further
confirmed by the existence of HNF1α response element in the promoter region of HNF1α-AS1 and
the positive expression correlation between HNF1α and HNF1α-AS1 in several HCC cell lines
and human HCC samples [169]. Early growth response protein 1, a transcription factor involved
in cancer development, was also reported to regulate expression of HNF1α-AS1 by directly
binding to the promoter region of HNF1α-AS1 and activating its transcription [179].
Guo and Lu reported that the expression of HNF4α-AS1 was strongly activated by P1-HNF4α,
which is predominantly produced in adult liver, but not P2-HNF4α, which is prevalent in fetal
liver, pancreas, and liver/colon cancer, indicating that HNF4α-AS1 might be a biomarker for P1HNF4α expression and might involve in the functional regulation of the liver-specific P1-HNF4α
[180].
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1.11.4 Mechanisms of HNF1α-AS1 and HNF4α-AS1 in gene regulation
Identifying the interacting molecules to lncRNAs is the key to understand the mechanisms
involved in lncRNA function. According to current literatures, HNF1α-AS1 functions by
interaction with miRNAs and proteins. However, what are the interacting molecules to HNF4αAS1 is still largely unknown.
HNF1α-AS1 has been reported to interact with miRNAs in cancer cells to regulate cell
characteristics including proliferation, movement, and apoptosis. By acting as a miRNA sponge,
HNF1α-AS1 was able to dis-inhibit the expression of genes by sponging miRNAs away from their
target genes. The miRNAs interacting with HNF1α-AS1 are summarized in Table 1.3.
HNF1α-AS1 was also reported to interact with functional proteins involved in cancer. Ding et
al. found that HNF1α-AS1 was able to directly bind to the C-terminal of Src homology region 2
domain-containing phosphatase 1 (SHP-1) with a high binding affinity [169]. SHP-1 is a nonreceptor protein tyrosine phosphatase, which predominantly expressed in haematopoietic cells,
and function as a negative regulator of inflammation and tumor suppressor. Inhibition of SHP-1
activity resulted in promoted tumor growth and metastasis [181]. SHP-1 was also reported to be
regulated by HNF1α in rat hepatocytes [182]. By interacting with SHP-1, HNF1α-AS1 increased
the phosphatase activity of SHP-1 and performed its tumor-suppressing function.
Furthermore, HNF1α-AS1 was reported to interact with enzymes or complexes involved in
epigenetic modification. Using RNA immunoprecipitation, HNF1α-AS1 was found to be able to
interact with DNA methyltransferase (cytosine-5) 1 (DNMT1) in A549 cell lines, and polycomb
repressive complex 2 member enhancer of zeste 2 (EZH2) complex in SMCC-7721 and Huh7 cell
lines [170,171]. DNMT1 and EZH2 are critical proteins involved in DNA methylation and histone
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methylation, respectively. These findings suggested that HNF1α-AS1 might regulate target genes
by altering their epigenetic markers through interaction with epigenetic modifying enzymes or
complexes.
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Table 1. 3. Summary of miRNAs interacting with HNF1α-AS1.

miRNA
miR-30b-5p

Cancer type
HCC，bladder cancer

Reference
[162,167]

miR-34a

colon cancer

[163]

miR-17-5p

NSCLC

[172]

miR-661

Gastric cancer

[179]

miR-149-5p

NSCLC

[183]

miR-34b

Cervical cancer

[176]

miR-124

Colorectal cancer

[173]
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1.12

Aim of the project

Despite the development in understanding lncRNAs functions, there is a lack of knowledge
about how lncRNAs may impact hepatic P450s and P450 mediated drug metabolism process. The
expression and function of P450 are critical to ensure drug efficacy and safety for clinical usages.
However, great interindividual variability exists in P450s and the mechanisms of P450 regulation
are still not fully understood yet. Identifying new regulatory factors and understating their
mechanisms are keys to promote the knowledge in P450 and drug metabolism, which also benefit
clinical drug use and safety.
The current research project is significantly relevant to the treatment of human diseases with
drugs. The goal of drug therapy is to achieve therapeutic efficacy and to avoid toxicity. To reach
these goals, it is critical to understand how drug-metabolizing enzymes are regulated. HNF1α and
HNF4α are two key transcription factors in the regulation of expression of certain drugmetabolizing enzymes, including some cytochrome P450s. However, how these transcription
factors regulate target P450s and other P450-regulating transcription factors are still largely
unknown.
The central hypothesis of the current research is HNF1α-AS1 and HNF4α-AS1, which are two
transcription factor neighborhood lncRNAs, are involved in the regulation of P450 genes, P450regulating transcription factors, and P450-mediated drug metabolism. In order to test this
hypothesis, the functional analysis of lncRNAs was performed by the generation of loss-offunction models with gene-editing techniques. Multiple assays are also used to test the effects of
lncRNA knockdown on gene and protein expression, cell viability, and cytotoxicity.
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The results generated in this research project will provide knowledge needed to unravel and
understand the roles of lncRNAs in drug metabolism.
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Chapter 2. A Transcriptional Regulatory Network
Containing Nuclear Receptors and lncRNAs Controls
Basal and Drug-Induced Expression of Cytochrome
P450s in HepaRG Cells

2.1 Introduction
Enzymes belonging to the cytochrome P450 (P450) superfamily are responsible for primarily
metabolizing of 70-80% prescription drugs [184]. Inter-individual variability in P450-mediated
drug metabolism exists in the general population, which leads to variability in therapeutic efficacy
and adverse drug reactions [5]. In addition to genetic polymorphisms in the P450 genes, the
variability in P450 expression is a major cause of inter-individual difference in P450-mediated
drug metabolism [185]. Therefore, it is critical to understand how P450 expression is regulated,
particularly at transcriptional level.
Transcription of P450 expression is regulated at two different conditions: normal physical
condition (basal level) and challenged conditions when exposing to drugs or xenobiotics (induced
level). It has been accepted that the basal expression of P450s is regulated by two key transcription
factors: HNF1α and HNF4α. HNF1α and HNF4α have been proven as key transcriptional
regulators in the control of expression of a wide range of hepatic genes at normal physical
conditions across different species, including various P450s [31,32,186-192]. HNF1α and HNF4α
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mainly control transcription of their target genes by direct DNA binding to the promoter regions
[193,194]. The existence of binding site for liver-enriched transcription factors in numerous liver
specific genes further supported the important role of HNF1α and HNF4α in hepatic gene
regulation [195,196].
The induced levels of P450s are controlled by two “xenobiotic sensor” nuclear receptors: CAR
and PXR. Activation of these nuclear receptors by drugs can result in induced expression of target
P450 genes [197-199]. CAR mainly regulates induction of CYP2B subfamily and can be activated
by phenobarbital (PB) [200]. PXR mainly regulates induction of CYP3A subfamily and can be
activated by rifampicin (RIF) [201].
Studies have shown the complexity of network interaction between nuclear receptors in the
regulation of P450s. HNF1α deficiency in mice has showed altered expression in several nuclear
receptors [32]. HNF4α has been shown to regulate PXR and CAR and effected induction of
downstream P450s [202]. Further, HNF4α was reported to positively regulate HNF1α [203].
However, no research studies the network among PXR, CAR, HNF1α, and HNF4α in a single
system.
Long non-coding RNAs (lncRNAs) refer to RNA transcripts longer than 200 nucleotides that
have no protein coding function [204,205]. Recent studies have showed that lncRNAs are involved
in regulation of neighborhood genes [114,206-209]. The involvement of lncRNAs has been shown
in multiple physiological processes, including metabolism and diseases [210,211]. The gene
coding for lncRNA HNF1α -AS1 is located on human chromosome 12, next to the HNF1α gene.
HNF1α -AS1 was first identified to regulate cell proliferation and migration of human esophageal
adenocarcinoma (EAC) cells [159]. Following studies showed that HNF1α -AS1 also involved in
tumorigenesis and metastatic progression of several other cancer types [161,168,170,212]. The
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gene coding for lncRNA HNF4α -AS1 is located on human chromosome 20, which overlaps with
HNF4α gene. Based on previous data on lncRNAs, we hypothesized that HNF1α -AS1 and HNF4α
-AS1 are involved in a transcription network with other transcription factors in the regulation of
expression of P450s.
HepaRG cells were selected as the experimental model due to a previous study showing that
HepaRG cells express comparable levels of P450s and transcription factors as human primary
hepatocytes [213]. Furthermore, HepaRG cells also respond to different P450 inducers and
inhibitors [214-216].
In order to study the control of expression of P450s by a regulatory network containing nuclear
receptors and lncRNAs, we used small interference RNA (siRNA) and small hairpin RNA (shRNA)
to perform gene knockdown in HepaRG cells and investigated the effects on expression of selected
nuclear receptors, lncRNAs, and P450s.

2.2 Materials and Methods
2.2.1 Chemicals and Reagents
HepaRG cells were kindly provided by Biopredic International (Rennes, France). ADD710
growth additives and ADD720 differentiation additives were purchased from Biopredic
International. William’s E Media (WEM), collagen I coated T-25 flasks, collagen I coated 12-well
plates, Glutamax™ Supplement, Opti-MEM medium were obtained from Thermo Fisher
Scientific (Carlsbad, CA). siRNAs, including a negative control (Catalog number: 4390843),
GAPDH (Catalog number: 4390849), CAR (siRNA ID: s19369), PXR (siRNA ID: 138582),
HNF4α (siRNA ID: s6698), HNF1α (siRNA ID: s13868), HNF1α -AS1 (siRNA ID: n265372),
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and HNF4α -AS1 (siRNA ID: n356309), Lipofectamine™ RNAiMAX transfection reagent, and
Lipofectamine™ stem transfection reagent were provided by Thermo Fisher Scientific (Carlsbad,
CA). shRNA negative control and shRNAs targeting HNF1Α -AS1 were obtained from
GeneCopoeia (Rockville, MD). Phenobarbital sodium salt and rifampicin were purchased from
Sigma-Aldrich (St. Louis, MO). Antibodies against GAPDH, CAR, and PXR were obtained from
Abcam (Cambridge, MA). Anti- HNF1α antibody and TRIzol™ reagent were purchased from
Invitrogen (Carlsbad, CA). Anti- HNF4α antibody and anti-rabbit IgG antibody were obtained
from Cell Signaling Technology (Danvers, MA).

2.2.2 Cell Culture
HepaRG cells were cultured following a protocol from Biopredic International. Briefly, a
three-step protocol was used to generate fully differentiated HepaRG cells. Cells were first thawed
and cultured in HepaRG growth medium (William’s E Media supplied with Glutamax™ and
ADD710 growth additives) for two weeks in order to reach full confluence. Cells were next
cultured in a 1:1 mixture of HepaRG growth medium and a HepaRG differentiation medium
(William’s E Media supplied with Glutamax™ and ADD720 growth additives) for one week. In
the last step, cells were cultured in HepaRG differentiation medium for another week to reach a
full differentiation status. During the whole process, cells were incubated at 37°C and 5% CO 2
with the medium changed every 3 days. Fully differentiated cells were either used directly in T-25
flash or trypsinized and seeded into collagen I coated 12-well plates for further treatment.
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2.2.3 siRNA Transfection
For siRNA transfection, fully differentiated HepaRG cells were transfected with different
siRNAs (negative control, HNF1α, HNF1α -AS1, HNF4α, HNF4α -AS1, CAR, and PXR) using
the Lipofectamine™ RNAiMAX Transfection Reagent according to manufacturer’s protocol.
Sixteen hours after transfection, the siRNA-containing medium was replaced with a normal
HepaRG differentiation medium. RNAs and proteins harvested at 48 hours after siRNA
transfection were used for knockdown efficiency and analysis of basal expression of P450s.

2.2.4 shRNA Transfection
For shRNA transfection, undifferentiated HepaRG cells were stably transfected with four
different shRNAs targeting HNF1α -AS1 or negative control shRNA using the Lipofectamine™
stem transfection reagent. Positive transfected cells were selected by puromycin treatment (3
μg/ml). After antibiotic selection, cells were cultured to full differentiated status and harvested for
RNA isolation.

2.2.5 Drug Treatment
For drug treatment, siRNA transfected HepaRG cells were treated with 1 mM phenobarbital
sodium salt, 10 µM rifampicin, or PBS (vehicle) for 24 hours. After drug treatment, RNAs were
isolated for analysis of P450 induction.
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2.2.6 RNA Isolation and Quantitative Real-Time PCR (RT-PCR)
Total RNAs were isolated from HepaRG cells using a TRIzol™ reagent according to the
manufacturer’s protocol. RNA concentration was measured by a Nano Drop spectrophotometer
(Nano Drop Technologies, Wilmington, DE) at 260 nm and RNA integrity was evaluated using an
Agilent 2200 Tape Station (Agilent Technologies, Santa Clara, CA). One µg of total RNAs was
subjected to cDNA synthesis using an iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories,
Hercules, CA). Real-time PCR was performed using a CFX96™ Real-Time System (Bio-Rad
Laboratories, Hercules, CA) with the primer sequences shown in Table 2.1. Expression of GAPDH,
HNF1α, HNF4α, CAR, PXR, AHR, HNF1α -AS1, CYP1A2, 2B6, 2C8, 2C9, 2C19, 2E1, and 3A4
were measured using an iTaq™ Universal SYBR® Green Supermix (Bio-Rad Laboratories,
Hercules, CA) and expression of HNF4α -AS1 was measured using a TaqMan™ Gene expression
assay (Life Technologies, Carlsbad, CA). Relative mRNA expression levels were determined by
normalizing examined gene expression against GAPDH expression using ΔΔCt method.
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Table 2. 1 List of primers used for real time PCR.

SYBR Primers (Integrated DNA Technologies, Coralville, IA)
Gene
GAPDH
CAR
PXR
Ahr
HNF1α
HNF4α
HNF1αAS1
CYP1A2
CYP2B6
CYP2C8
CYP2C9
CYP2C19
CYP2E1
CYP3A4

Primer Sequence
Forward
5′-GGGAGCCAAAAGGGTCAT-3′
Reverse
5′-GAGTCCTTCCACGATACCAA-3′
Forward
5’-TGATCAGCTGCAAGAGGAGA-3’
Reverse
5’-AGGCCTAGCAACTTCGCATA-3’
Forward
5’-CCAGGACATACACCCCTTTG-3’
Reverse
5’-CTACCTGTGATGCCGAACAA-3’
Forward
5’-ACATCACCTACGCCAGTCGC-3’
Reverse
5’-TCTATGCCGCTTGGAAGGAT-3’
Forward
5'‐CCCTGGGTCCTACGTTCA‐3'
Reverse
5'‐GGGTCACATGGCTCTGCA-3’
Forward
5’-CGTGCTGCTCCTAGGCAA-3’
Reverse
5’-GTCAAGGATGCGTATGGACAC-3’
Forward
5′-TCAAGAAATGGTGGCTAT-3′
Reverse
5′-GCTCTGAGACTGGCTGAA-3’
Forward
5’-CCAACGTCATTGGTGCCATG-3’
Reverse
5’-GTGATGTCCCGGACACTGTTC-3’
Forward
5’-AGACGCCTTCAATCCTGACC-3’
Reverse
5’-CCTTCACCAAGACAAATCCGC-3’
Forward
5’-GGACTTTATGGATTGCTTCCTG-3’
Reverse
5’-CCATATCTCAGAGTGGTGCTTG-3’
Forward
5’-GACATGAACAACCCTCAGGACTTT-3’
Reverse
5’-TGCTTGTCGTCTCTGTCCCA-3’
Forward
5’-GAACACCAAGAATCGATGGACA-3’
Reverse
5’-TCAGCAGGAGAAGGAGAGCATA-3’
Forward
5’-AATGGACCTACCTGGAAGGAC-3’
Reverse
5’-CCTCTGGATCCGGCTCTCATT-3’
Forward
5’-GATTGACTCTCAGAATTCAAAAGAAACTGA-3’
Reverse
5’-GGTGAGTGGCCAGTTCATACATAATG-3’

TaqMan™ primer (Life Technologies, Carlsbad, CA)
Gene

Assay ID

GAPDH

Hs99999905_m1

HNF4α-AS1 Hs01378672_m1
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2.2.7 Protein Sample Preparation and Quantification by Western Blotting
Cell lysates were prepared from HeapRG cells cultured in collagen I coated T-25 flasks with
RIPA buffer (supplied with protease inhibitor cocktail). Protein concentrations were determined
using a Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA). Eighty µg of proteins were loaded and
run on a polyacrylamide gel using a Mini-PROTEAN Tetra System (Bio-Rad Laboratories,
Hercules, CA). Proteins were then transferred onto a PVDF membrane and blocked in 5% BSA
for 1 hour. After blocking, the membrane was incubated with an antibody diluted in 2.5% BSA
(anti-GAPDH 1:4000, anti-HNF1α 1:1000, anti-HNF4α 1:1000, anti-CAR 1:500, and anti-PXR
1:1000) overnight. Then the membrane was incubated in an anti-rabbit IgG antibody (1:2000)
diluted in 2.5% BSA. Protein bands were visualized using a ChemiDoc MP Imaging System (BioRad, Hercules, CA). Semi quantification of proteins was calculated as the relative expression
against GAPDH using an ImageJ program (National Institutes of Health, USA).

2.2.8 Statistical Analysis
The data are shown as mean ± SD (standard deviation). The significance of differences
between means was determined using a two-tailed unpaired Student’s t test. Statistical analyses
were performed using Prism7, version 7.01 from GraphPad Software, Inc. (La Jolla, CA, USA).
Differences were regarded as statistically significant if p < 0.05.

68

2.3 Results
2.3.1 Impact on Regulation of P450s by Knockdown of CAR
To evaluate the role of CAR in affecting expression of the selected transcription factors,
lncRNAs, and P450s, HepaRG cells were transfected with a siRNA targeting CAR and mRNA
expression of the selected genes were evaluated by RT-PCR. Knockdown efficiency of CAR after
siRNA transfection into HepaRG cells was confirmed with a decrease of 76% in mRNA level
determined by RT-PCR and a decrease of 65% in protein level detected by Western blot (Figure
2.1A). Next, the mRNA expression of other examined transcription factors involved in P450
regulation was analyzed. As shown in Figure 2.1B, mRNA expression of HNF4α, HNF1α, PXR,
and AHR was not affected by CAR knockdown. Expression of lncRNAs, HNF4α -AS1 and
HNF1α -AS1, were also not affected by CAR knockdown (Figure 2.1C). Among the selected drugmetabolizing P450s, basal mRNA expression of CYP2B6, 2E1, and 3A4, which were known CAR
regulated P450s, showed statistically significant decreases (Figure 2.1D). In contrast, mRNA
expression of CYP1A2 was increased in HeapRG cells with CAR knockdown (Figure 2.1D). To
measure the effect of CAR knockdown to drug-induced P450 expression, HepaRG cells were
treated with either PB or RIF after CAR knockdown by siRNA. As shown in Figure 2.1E, the
induction levels were lower for CYP2B6 (3.4 fold change to 1.5 fold change in the induction level
after CAR knockdown by PB treatment), 2C19 (2.9 fold change to 1.6 fold change in the induction
level after CAR knockdown by PB treatment), and 3A4 (9.3 fold change to 4.3 fold change in the
induction level after CAR knockdown by PB treatment) (Figure 2.1E).
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Figure 2. 1. Changes of gene expression by CAR knockdown.
(A) Suppression of CAR expression in both mRNA (left) and protein (right) levels by siRNA
transfection into HepaRG cells. (B) Expression of the selected transcription factors after CAR
knockdown. (C) Expression of HNF4α -AS1 or HNF1α -AS1 after CAR knockdown. (D)
Expression of the selected P450s at basal levels after CAR knockdown. (E) Expression of the
selected P450s at induced levels with treatment of either phenobarbital (PB) or rifampicin (RIF)
after CAR knockdown. The sample size for each group is n = 3. Data are shown as mean ± SD. *p
< 0.05, **p < 0.01, and ***p < 0.001 versus control in two-tailed unpaired Student’s t tests.
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2.3.2 Impact on Regulation of P450s by Knockdown of PXR
The role of PXR in expression of the selected transcription factors, lncRNAs, and P450s was
studied with a similar experimental design as CAR. Knockdown efficiency of PXR was evaluated
by RT-PCR and Western blot after siRNA transfection into HepaRG cells. As shown in Figure
2.2A, expression of PXR mRNA and protein was decreased to approximately 43% and 40% of the
control, respectively. Expression of HNF4α, HNF1α, and AHR was not affected by PXR
knockdown, while expression of CAR decreased after PXR knockdown (Figure 2.2B). For
lncRNAs, there were slight decreases in expression of HNF4α -AS1 and HNF1Α-AS1 with no
statistical significance (Figure 2.2C). For basal P450 expression, only PXR regulated P450s,
CYP2B6 and 3A4, were decreased, whereas CYP1A2 was increased (Figure 2.2D). Furthermore,
induction of the PXR regulated P450s was significantly repressed by PXR knockdown compared
to the control group, for example, CYP2B6 (3.4 fold change to 1.6 fold change in the induction
level after PXR knockdown by PB treatment) and 3A4 (9.3 fold change to 1.4 fold change in the
induction level after PXR knockdown by PB treatment and 4.7 fold change to 1.6 fold change in
the induction level after PXR knockdown by RIF treatment) with statistical significance.
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Figure 2. 2. Changes of gene expression by PXR knockdown.
(A) Suppression of PXR expression in both mRNA (left) and protein (right) levels by siRNA
transfection into HepaRG cells. (B) Expression of the selected transcription factors after PXR
knockdown. (C) Expression of HNF4α -AS1 or HNF1α -AS1 after PXR knockdown. (D)
Expression of the selected P450s at basal levels after PXR knockdown. (E) Expression of the
selected P450s at induced levels with treatment of either phenobarbital (PB) or rifampicin (RIF)
after PXR knockdown. The sample size for each group is n = 3. Data are shown as mean ± SD. *p
< 0.05, **p < 0.01, and ***p < 0.001 versus control in two-tailed unpaired Student’s t tests.
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2.3.3 Impact on Regulation of P450s by Knockdown of HNF1α
Next, the role of HNF1α was studied in an experiment with the same design as CAR and PXR.
Transfection of siHNF1α resulted in a decrease of 54% in HNF1α mRNA level and a decrease of
59% in HNF1α protein level (Figure 2.3A). HNF1α knockdown also repressed mRNA expression
of PXR and CAR, while increased mRNA expression of AHR. The expression of HNF4α was not
affected (Figure 2.3B). For lncRNAs, the expression of HNF4α -AS1 was not affected (Figure
2.3C). However, HNF1α knockdown caused a decrease of 85% of HNF1α -AS1 expression as
shown in Figure 2.3C. HNF1α knockdown also affected the expression of multiple P450s in both
basal and induction levels. Basal expression of CYP2B6, 2C8, 2C9, 2C19, 2E1, and 3A4 showed
decreases with statistical significance (Figure 2.3D). The expression of CYP2B6 and 3A4 was still
induced by treatment with either PB or RIF, but in a much lower fold compared to the control
group. Furthermore, the induction of CYP2C8, 2C9, and 2C19 was completely abolished by
HNF1α knockdown (Figure 2.3E).
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Figure 2. 3. Changes of gene expression by HNF1 knockdown.
(A) Suppression of HNF1 expression in both mRNA (left) and protein (right) levels by siRNA
transfection into HepaRG cells. (B) Expression of the selected transcription factors after HNF1
knockdown. (C) Expression of HNF4-AS1 or HNF1-AS1 after HNF1 knockdown. (D)
Expression of the selected P450s at basal levels after HNF1 knockdown. (E) Expression of the
selected P450s at induced levels with treatment of either phenobarbital (PB) or rifampicin (RIF)
after HNF1 knockdown. The sample size for each group is n = 3. Data are shown as mean ± SD.
*p < 0.05, **p < 0.01, and ***p < 0.001 versus control in two-tailed unpaired Student’s t tests.
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2.3.4 Impact on Regulation of P450s by Knockdown of HNF4α
Cells transfected with siHNF4α showed 60% less expression of HNF4α mRNA and almost
depleted expression of HNF4α protein (Figure 2.4A). In the analysis of the selected transcription
factors, expression levels of HNF1α, PXR, and CAR all decreased, while AHR expression
increased with HNF4α knockdown (Figure 2.4B). Expression of both lncRNAs was almost
depleted with approximately a decrease of 90% in HNF4α-AS1 expression and a decrease of 63%
in HNF1α-AS1 expression (Figure 2.4C). HNF4α knockdown also decreased basal expression of
CYP2B6, 2C8, 2C9, 2C19, 2E1, and 3A4, but to a much greater extent than HNF1α knockdown
(Figure 2.4D). P450 induction by treatment with PB or RIF was also largely diminished by HNF4α
knockdown (Figure 2.4E).

78

79

Figure 2. 4. Changes of gene expression by HNF4 knockdown.
(A) Suppression of HNF4 expression in both mRNA (left) and protein (right) levels by siRNA
transfection into HepaRG cells. (B) Expression of the selected transcription factors after HNF4
knockdown. (C) Expression of HNF4-AS1 or HNF1-AS1 after HNF4 knockdown. (D)
Expression of the selected P450s at basal levels after HNF4 knockdown. (E) Expression of the
selected P450s at induced levels with treatment of either phenobarbital (PB) or rifampicin (RIF)
after HNF4 knockdown. The sample size for each group is n = 3. Data are shown as mean ±
SD. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control in two-tailed unpaired Student’s t
tests.
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2.3.5 Impact on Regulation of P450s by Knockdown of HNF1α-AS1
To study the role of the lncRNAs in the regulatory network in control of expression of P450s,
HepaRG cells were first transfected with siRNA or shRNA to knock down HNF1α-AS1. As shown
in Figure 2.5A, siRNA and shRNA transfection decreased HNF1α -AS1 expression by
approximately 40% and 75%, respectively. In terms of transcription factors, HepaRG cells
transfected with siHNF1α-AS1 only showed decreased mRNA expression of CAR, while HNF1α,
HNF4α, PXR, and AHR remained unchanged. However, HepaRG cells transfected with
shHNF1α-AS1 showed decreased mRNA expression in all examined transcription factors, among
which HNF4α, HNF1α, and AHR had only a minor decrease (15%, 28%, and 22%, respectively),
while CAR and PXR had a major decrease (55% and 65%, respectively) (Figure 2.5B). Expression
of lncRNA HNF4α -AS1 was only affected by shHNF1α-AS1 transfection with a decrease of 33%
Figure 2.5C). Basal expressions of several P450s were also affected by HNF1α-AS1 knockdown.
HepaRG cells transfected with siHNF1α-AS1 showed an increase in CYP1A2 expression and a
decrease in CYP2E1 expression with statistical significance, companied with minor decreases in
CYP2B6, 2C8, and 2C9 (Figure 2.5D). HepaRG cells transfected with shHNF1α-AS1 showed
extensively repressed effects on all examined P450s (Figure 2.5D).
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Figure 2. 5. Changes of gene expression by HNF1α-AS1 knockdown.
(A) Suppression of HNF1-AS1 expression by siRNA or shRNA transfection into HepaRG
cells. (B) Expression of the selected transcription factors after HNF1-AS1 knockdown. (C)
Expression of HNF4-AS1 after HNF1-AS1 knockdown. (D) Expression of the selected P450s
at basal levels after HNF1-AS1 knockdown. The sample size for each group is n = 3. Data are
shown as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control in two-tailed
unpaired Student’s t tests.
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2.3.6 Impact on Regulation of P450s by Knockdown of HNF4α-AS1
The role of HNF4α-AS1 in the regulatory network in control of expression of P450s was also
studied in HepaRG cells transfected with siRNA targeting HNF1α -AS1. HNF4α -AS1 expression
was decreased approximately 70% by siRNA transfection (Figure 2.6A). Next, the expressions of
the selected transcription factors were determined. Expression of HNF4α and HNF1α were
increased slightly and expression of CAR was increased dramatically after HNF4α-AS1
knockdown, while expression of AHR was decreased with statistical significance (Figure 2.6B).
Knockdown of HNF4α -AS1 did not affect expression of HNF1α -AS1 (Figure 2.6C). mRNA
expressions of the selected P450s were measured. As shown in Figure 2.6D, all selected P450s,
expect CYP2C8, had increased the expression after HNF4α -AS1 knockdown with statistical
significance.
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Figure 2. 6. Changes of gene expression by HNF4-AS1 knockdown.
(A) Suppression of HNF4-AS1 expression by siRNA transfection into HepaRG cells. (B)
Expression of the selected transcription factors after HNF4-AS1 knockdown. (C) Expression of
HNF1-AS1 after HNF4-AS1 knockdown. (D) Expression of the selected P450s at basal levels
after HNF4-AS1 knockdown. The sample size for each group is n = 3. Data are shown as mean
± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control in two-tailed unpaired Student’s t
tests.
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2.4 Discussion
Transcription factors play a prominent role in the regulation of P450 expression [193,196]. In
the present study, we studied the functions of CAR, PXR, HNF1α, and HNF4α. In addition,
HNF1α-AS1 and HNF4α-AS1, which are the neighborhood lncRNAs of HNF1α and HNF1α, were
also selected to test their roles in the regulation of P450 expression. Efficient knockdown of target
genes was performed by siRNA or shRNA transfection into HepaRG cells. The effects on
transcription of the selected transcription factors, lncRNAs, and drug-metabolizing P450 genes
were measured by quantitative RT-PCR.
CAR and PXR have been reported to regulate expression of specific P450 subfamilies of
CYP2Bs and CYP3As, respectively [200,201]. In our experiment, knockdown of CAR or PXR
only showed a minor effect on expression of other transcription factors or lncRNAs (Figure 2.1B,
1C, 2B, and 2C). Knockdown of CAR decreased basal and phenobarbital-induced expression of
CYP2B6 (Figure 2.1D and 1E), whereas knockdown of PXR reduced basal and rifampicin-induced
expression of CYP3A4 (Figure 2.2D and 2E) in HepaRG cells. In addition, CAR knockdown also
showed a minor effect on phenobarbital-induced expression of CYP2C and 3A families (Figure
2.1E), while PXR knockdown showed slightly diminished phenobarbital-induced expression of
CYP2B and 2C families (Figure 2.2E).
The role of HNF1α in the regulation of multiple hepatic expressions of P450s has previously
been studied in an HNF1α -deficient mouse model [32]. Our data showed that HNF1α knockdown
in HepaRG cells led to decreased expression of PXR and CAR, while increased expression of AhR.
Knockdown of HNF1α in HepaRG cells also decreased the basal mRNA levels of CYP2B6, 2C8,
2C9, 2C19, 2E1, and 3A4, while increased mRNA level of CYP1A2 (Figure 2.3D). Compared
with HNF1α-deficient mice data, we observed a similar regulation pattern in CYP2C and 2E
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subfamilies and an opposite regulation pattern in CYP1A, 2B, and 3A subfamilies. Furthermore,
the phenobarbital- and rifampicin-induced levels of the most examined P450s were also greatly
inhibited by HNF1α knockdown, where the inhibition of CYP2B and 3A subfamilies might be at
partially due to decreased expression of CAR and PXR (Figure 2.3E).
The role of HNF4α in the regulation of hepatic P450 genes has been studied in several species.
In HepaRG cells, we found that HNF4α knockdown decreased the expression of HNF1α, CAR,
and PXR, while increased expression of AhR (Figure 2.4B). Similar to HNF1α knockdown,
HNF4α knockdown led to decreased expression of CYP2B6, 2C8, 2C9, 2C19, 2E1, and 3A4, while
increased the CYP1A2 expression (Figure 2.4D). In addition, the phenobarbital- and rifampicininduced P450 expression was greatly inhibited, which might be partially contributed by decreased
CAR and PXR (Figure 2.4E).
In the current study, we found that knockdown of HNF1α and HNF4α was able to decrease the
expression of PXR and CAR. This agreed with previous data showing HNF4α crosstalk with PXR
and CAR in the regulation of P450 expression [217,218]. In addition, HNF4α has also been
reported to directly regulate expression of PXR and CAR and sequential induction of P450s
through these two nuclear receptors [202,219].
The interaction between HNF1α and HNF4α has been documented in several previous studies
[203,220]. A study showed that HNF4α positively regulates HNF4α in rat hepatoma cells,
evidenced by deleting the HNF4α binding site in the promoter region of the HNF1α gene abolished
the promoter activity [203]. Another study showed that HNF1α was able to negatively regulate
HNF4α, evidenced by the identification of a binding site of HNF1α in the HNF4α promoter region
[220]. However, in the study on HNF1α -deficient mice, the expression of HNF4α was not changed
[32]. In our result, HNF1α knockdown only had a minor effect on mRNA expression of HNF4α
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(Figure 2.3B), which agreed with the mouse data. HNF4α knockdown decreased mRNA
expression of HNF1α with statistical significance (Figure 2.4B), which agreed with the rat
hepatoma cell data. Our data imply the existence of a transcription regulatory network containing
transcription factors of HNF1α, HNF4α, and CAR/PXR in an order to control the basal and druginduced expression of major P450s involved in drug metabolism.
In recent years, utilizing the encyclopedia of DNA elements (ENCODE) project, studies have
revealed that over 70% of the human genome are capable of being transcribed into RNAs [221].
However, not all the transcribed primary RNAs have protein coding ability. In human, only
approximate 2% of the transcribed RNAs are translated into proteins [42]. Other than
housekeeping non-coding RNAs (ribosomal RNAs, transfer RNAs, and small nuclear RNAs),
whose biological functions have been well defined, regulatory non-coding RNAs (siRNAs,
microRNAs, and long non-coding RNAs) have recently shown to be actively involved in
physiological regulations [210,221]. Further, lncRNAs have been shown to perform transcriptional
regulation through interaction with transcription factors in different tissues [111,222].
We identified two lncRNAs as our interested target lncRNAs, HNF1α -AS1 and HNF4α -AS1,
which are located in the neighborhood regions of the HNF1α and HNF1α genes, respectively.
Evidence has shown that antisense lncRNAs are likely to involve in the regulatory functions of
their neighborhood coding genes [114]. Hence, we examined the role of two selected lncRNAs in
the regulation of P450 expression. We found that the expression of HNF1α -AS1 and HNF4α AS1 is largely dependent on its neighborhood transcription factors HNF1α and HNF4α
respectively. HNF1α knockdown depleted the expression of HNF1α -AS1 without alteration of
expression of HNF4α -AS1 (Figure 2.3C). The knockdown of HNF4α decreased expression of
both HNF1α -AS1 and HNF4α -AS1 (Figure 2.4C). We believed that HNF4α -AS1 was dependent
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on the expression of HNF4α and decreased expression of HNF1α after HNF4α knockdown was
responsible for the decrease of HNF1α -AS1.
In the lncRNA knockdown experiments, HNF1α -AS1 knockdown by siRNA and shRNA
showed very similar regulation trends on most examined genes (Figure 2.5). Knockdown of
HNF1α -AS1 by shRNA decreased mRNA expression of all examined transcription factors and
basal levels of P450s as well as expression of HNF4α -AS1 (Figure 2.5B, 5C, and 5D). The effect
of HNF1α -AS1 knockdown was very similar to HNF1α knockdown, indicating that HNF1α -AS1
might work as a downstream co-factor of HNF1α in the regulation of other transcription factors
and P450s. The knockdown of HNF4α-AS1 showed opposite regulatory effects on almost all
examined genes compared to knockdown of HNF1α, HNF4α, and HNF1α -AS1 (Figure 2.6B, 6C,
and 6D), indicating the potential inhibitory role of HNF4α -AS1 in the regulation of P450s by the
transcription factor network. These results confirmed our hypothesis that the lncRNAs of HNF1α
-AS1 and HNF4α -AS1 participate in the regulation of drug-metabolizing P450 enzymes.
Even though we have observed involvement of the lncRNAs in the regulation of P450
expression; the underlying mechanisms are still unclear. Several mechanisms in regulation of gene
expression by lncRNAs have been identified at different levels of gene expression, including
transcriptional and post-transcriptional regulation levels [209,223]. Generally, the regulatory roles
of lncRNAs depend on interacting with partner molecules, such as proteins, RNAs, and DNAs
[114]. Proteins are believed to be the major binding partners of lncRNAs due to the discovery of
distinct protein binding domains on lncRNAs. By binding with protein molecules, lncRNAs can
either work as scaffold molecules to promote the formation of protein complexes or work as guide
molecules to move proteins to a specific location. Depending on which protein is recruited,
lncRNAs can have different impacts on expression of their regulating target genes [224].
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Interactions between lncRNAs and other RNAs can regulate targeted RNA properties, including
RNA stability and translation efficiency. For example, an antisense lncRNA located next to mouse
coding gene Uchl1 is able to regulate the translation efficiency of UCHL1 protein through
activation of polysomes [225]. Several specific examples have revealed the interactions between
lncRNAs and DNAs, but whether these interactions are widespread in a genome is still unclear.
For example, a noncoding RNA, promoter associated RNA (pRNA), has shown to mediate de novo
methylation of its targeted DNAs by forming a DNA: RNA triplex, which can be recognized by
DNA methyltransferases [226]. All evidence suggested that lncRNAs are associated with the
complexity of gene regulation processes. Based on current assays, we will study how HNF1α-AS1
and HNF4α-AS1 regulate their targeted genes and involve in the regulation network in control of
basal and drug-induced expression of P450s in future experiments.
In conclusion, the present study demonstrates the existence of a transcription regulatory
network controlling the expression of P450s in HepaRG cells (Figure 2.7). Several levels of P450
regulation can be found in the current study. HNF1α and HNF4α were regarded as the master
regulators to all other components. HNF1α and HNF4α positively regulated the expression of their
neighborhood lncRNAs, PXR, CAR, and tested P450s. In the next level of regulation, PXR and
CAR were found to positively regulate the expression of specific P450s, while no regulatory effect
was found to other tested transcription factors or lncRNAs. In terms of lncRNAs, HNF1α-AS1 and
HNF4α-AS1 were shown to regulate PXR, CAR, and P450s, while only had minor regulatory
effects to their neighborhood coding genes. HNF1α-AS1 was shown to positively regulate the
expression of PXR, CAR, and several P450s, while HNF4α-AS1 had the opposite effect.
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Figure 2. 7. P450 regulatory network in HepaRG cells
Red arrows indicate positive regulatory effects. Blue arrows indicated negative regulatory
effects. The width of the arrow indicates the strength of the regulation, a thick arrow indicates
strong regulation and a thin arrow indicates weak regulation.
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Chapter 3. Knockdown of LncRNAs HNF1α-AS1 and
HNF4α-AS1 Alters Susceptibility of Acetaminopheninduced Cytotoxicity in HepaRG Cells

3.1 Introduction
Acetaminophen (APAP), or N-acetyl-p-aminophenol, is one of the most commonly used overthe-counter drugs for its antipyretic or analgesic effects in the treatment of fever or management
of pain [227]. APAP is a safe drug if used properly. The maximal dose of 4,000 mg per day
suggested by the US Food and Drug Administration is considered to be safe and generally does
not cause liver toxicity [228]. However, APAP overdose can result in severe APAP-induced liver
injury (AILI). Previous reports have indicated that AILI is one of the most common causes of liver
damage and acute liver failure in the United States [229,230]. Furthermore, APAP-related deaths,
mostly caused by liver failure, are much more than those liver failure fatalities caused by all other
prescription drugs combined [231]. Considerable efforts have been made to understand the
mechanisms responsible for AILI in different in vivo and in vitro models. N-acetyl-p-benzoquinone
imine (NAPQI), the active metabolite of APAP by cytochrome P450s (CYPs), has been proven to
cause cellular stress and damage through several pathways, including induction of oxidative stress
[232]. In this case, the metabolism of APAP by CYPs to NAPQI has been regarded as a critical
step in the development of AILI [233].
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CYPs are a group of heme-containing enzymes, which catalyze the metabolism of a broad
range of endogenous compounds, environmental chemicals, and drugs [234]. The expression and
function of CYPs are critical factors in the maintenance of human health and therapeutic efficacy
of drugs. However, great inter-individual variability has been observed in CYP expression and
functions as well as CYP-mediated drug metabolism [235]. Several CYP subfamily members,
including CYP1A2, 2E1, and 3A4, have been proven to mediate biotransformation of APAP to
NAPQI, which are important mediators for predicting AILI [236].
Multiple regulatory factors and mechanisms are involved in the regulation of CYP expression.
Genetic and epigenetic regulations are among the most widely studied factors contributing to
differential metabolism of drugs among individuals [5,17,237]. Furthermore, recent studies also
showed that several factors known to affect APAP-metabolizing CYP enzymes are able to alter
APAP metabolism and AILI outcome [238]. However, these studies mainly focus on the roles of
genetic polymorphisms in the CYP genes, which can only account for a small portion of the interindividual differences in expression of CYPs and ability to metabolize drugs [239]. More factors
and mechanisms are needed to be discovered to fully understand this process.
LncRNAs are RNA transcripts from non-coding genes with a length of more than 200
nucleotides [204]. Recent studies have shown that the overwhelmingly abundant lncRNAs,
comparing to coding RNAs, in human and other species have important functions in multiple
physiological processes, including development, cell differentiation, and immune response [240243]. Increasing evidence shows that lncRNAs are also important for the metabolism processes
[210,244]. However, how lncRNAs regulate CYP-mediated drug metabolism and the toxicological
consequences on CYP-generated metabolites are still not fully understood.
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Neighborhood antisense lncRNAs are a common phenomenon in multiple living organisms,
including human [114]. Several examples have suggested that the existence of neighborhood
antisense lncRNAs is critical for the function of their neighborhood coding genes [123,245].
LncRNAs hepatocyte

nuclear

factor

1α

(HNF1α) antisense

RNA

1

(HNF1α-AS1)

and HNF4α antisense RNA 1 (HNF4α-AS1) are neighborhood antisense lncRNAs of the
transcription factors HNF1α and HNF4α, respectively. These two lncRNAs have been reported to
regulate mRNA levels of several CYPs (including CYP1A2, 2E1, and 3A4) in opposing manners
in in vitro models [246,247]. Based on this observation, we hypothesize that the lncRNAs HNF1αAS1 and HNF4α-AS1 have opposite effects modulating AILI via alterations in APAP metabolism
by CYPs. To test the hypothesis, transfection of small hairpin RNA (shRNA) containing vectors
were used to knock down HNF1α-AS1 and HNF4α-AS1 in HepaRG cells, a reliable in vitro model
to study hepatotoxicity caused by APAP [248]. Cytotoxicity generated by APAP was determined
by

several

different

toxicity

assays,

including

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide (MTT) assay, lactate dehydrogenase (LDH) release, and
dihydrorhodamine 123 (DHR123) staining assays. Alterations in mRNA and protein levels of
APAP-metabolizing phase I and II enzymes were determined by quantitative real-time PCR (RTPCR) and Western blots, respectively.
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3.2 Materials and Methods

3.2.1 Chemicals and Reagents
HepaRG cells, HepaRG growth additives (Catalog number: ADD710), and HepaRG
differentiation additives (Catalog number: ADD720) were obtained from Biopredic International
(Rennes, France). William’s E Medium, collagen I coated T-25 flasks, collagen I coated 12-well
plates, collagen I coated chamber slides, Glutamax™ supplement, Opti-MEM medium,
Lipofectamine™ stem transfection reagent, MTT, Pierce LDH Cytotoxicity Assay Kit, and
DHR123 were obtained from Thermo Fisher Scientific (Carlsbad, CA). A shRNA negative control
and shRNAs targeting HNF1α-AS1 or HNF4α-AS1 were obtained from GeneCopoeia (Rockville,
MD). APAP was obtained from Sigma-Aldrich (St. Louis, MO). An antibody against
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was purchased from Abcam (Cambridge,
MA). Antibodies against CYP1A2 and 2E1 were purchased from Proteintech (Rosemont, IL). An
anti-rabbit IgG antibody was obtained from Cell Signaling Technology (Danvers, MA). The
TRIzol™ reagent was obtained from Invitrogen (Carlsbad, CA).

3.2.2 Cell Culture
HepaRG cells were cultured according to the provider’s protocol. Briefly, the HepaRG cells
were cultured in a three-step manner. Thawed cells were firstly cultured in a HepaRG growth
medium (William’s E Medium supplied with Glutamax™ and growth additives) for two weeks
until cells became fully confluent. Cells were then kept in a mixture of HepaRG growth medium
and HepaRG differentiation medium (William’s E Medium supplied with Glutamax™ and
differentiation additives) for another week. Lastly, cells were cultured in a HepaRG differentiation
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medium for one more week when cells were fully differentiated. Cells were incubated in a
humidified cell incubator at 37°C with 5% CO2.

3.2.3 shRNA Transfection
To generate lncRNA loss-of-function HepaRG models, plasmid vector-containing shRNAs
with different targets were designed and purchased from GeneCopoeia (Rockville, MD, USA).
The transfection processes were performed according to a previous study with minor modifications
[249]. Briefly, HepaRG cells are seeded in collagen I coated 6-well plates with a concentration of
~50,000 cells/well. Plasmid transfection was performed when the cells reached to ~90%
confluence. Liposomes were prepared by mixing 1 μg shRNA-containing vector in 50 µL OptiMEM medium with 5 µl Lipofectamine™ stem transfection reagent in 50 µl Opti-MEM. After
incubation for 20 minutes at room temperature, the DNA-lipid complexes were added to HepaRG
cells. A puromycin selection (3 μg/ml) was performed after the transfection to select transfected
cells. Cells were then cultured to a fully differentiated status.

3.2.4 APAP Treatment
Differentiated HepaRG cells (transfected with shNC, shHNF1α-AS1, or shHNF4α-AS1) were
seeded into collagen-I coated 96-well plates with a density of 20,000 cells/well. Cells were
incubated overnight for attachment before treatment. Cells were then treated with 0, 10, 30, or 100
mM of APAP in PBS for 24 h.
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3.2.5 MTT Assay
Cell viability was measured by the MTT assay according to the manufacturer’s protocol.
Briefly, after APAP treatment, 20 µL of MTT solution (4 mg/ml) was added to each well and the
plates were incubated for 3.5 h in a 37°C incubator. After incubation, the remaining solution was
removed carefully from the plates and 100 µL of dimethyl sulfoxide (DMSO) was added to each
well to dissolve formed crystal. The plates were then agitated on an orbital shaker for 15 min for
completed dissolution. Absorbance of solution was then measured at 570 nm with a
spectrophotometric plate reader. Cell viability was calculated as percentage of the control group.

3.2.6 LDH Assay
Cell damage was measured by the LDH release assay according to the manufacturer’s protocol.
Same as the MTT assay above, one set of cells serving as a positive control was added with 10 µL
lysis buffer after APAP treatment, while another set of cells was added with 10 µL sterile water.
Cells were then incubated for 45 min in a cell incubator. After incubation, 50 µL supernatant of
each sample was transferred into a new 96-well flat bottom plate. A reaction mixture (50 µL) was
then added to each sample followed by gentle mixing. Plates were then incubated at room
temperature for 30 min protected from light. After a final incubation, 50 µL of the stop solution
were added to each sample with gentle mixing. Absorbance at 490 and 680 nm was measured with
a spectrophotometer and LDH activity was calculated as the difference in absorbance between 680
and 490 nm. The level of cell damage was represented by the ratio of LDH activities between a
sample and its positive control.
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3.2.7 DHR123 Staining
Oxidative stress in HepaRG cells after APAP treatment was measured by DHR123 staining.
Differentiated HepaRG cells (transfected with shNC, shHNF1α-AS1, or shHNF4α-AS1) were
seeded into collagen-I coated chamber slides with a density of 100,000 cells/well and incubated
overnight for attachment. Cells were then treated with 10 mM of APAP in a 500-µL culturing
medium for 24 h. After the treatment, the medium was removed and cells were rinsed once with
PBS. Diluted DHR123 solution (5 µM) was then added to each well and plates were incubated for
45 min with protection from light. After incubation, the DHR123 solution was replaced with PBS.
Images of fluorescent stained cells at ×400 magnification were taken using an EVOS Fluorescence
Microscope (Thermo Fisher Scientific, Carlsbad, CA). Quantification of fluorescence signals was
performed with ImageJ software (NIH).

3.2.8 RNA Isolation and Quantitative Real-Time PCR (RT-PCR)
Total RNAs were isolated from HepaRG cells using a TRIzol™ reagent according to the
manufacturer’s protocol. RNA concentration was measured by a Nano Drop spectrophotometer
(Nano Drop Technologies, Wilmington, DE) at 260 nm and RNA integrity was evaluated using an
Agilent 2,200 Tape Station (Agilent Technologies, Santa Clara, CA). One µg of total RNAs was
subjected to cDNA synthesis using an iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories,
Hercules, CA). RT-PCR was performed using a CFX96™ Real-Time System (Bio-Rad
Laboratories, Hercules, CA) with the primer sequences shown in Table 3.1. RNA or mRNA levels
of GAPDH, HNF1α-AS1, CYP1A2, 2E1, 3A4, SULT1A1, UGT1A1, 1A9, GSTP1, and GSTT1
were measured using an iTaq™ Universal SYBR® Green Supermix (Bio-Rad Laboratories,
Hercules, CA). RNA level of HNF4α-AS1 was measured by a TaqMan™ Gene expression assay
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(Life Technologies, Carlsbad, CA). Relative mRNA levels were determined by normalizing
examined gene expression against mRNA level of GAPDH using the 2-ΔΔCt method.

3.2.9 Protein Sample Preparation and Western Blotting
Cell lysates were prepared from HeapRG cells cultured in a collagen-I coated T-25 flask with
a RIPA buffer (supplied with protease inhibitor cocktail). Protein concentrations were determined
using a Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA). Eighty µg of protein was loaded and
run on a polyacrylamide gel using a Mini-PROTEAN Tetra System (Bio-Rad Laboratories,
Hercules, CA). Proteins were then transferred onto PVDF membranes and blocked in 5% bovine
serum albumin (BSA) for 1 h. After blocking, membranes were incubated with primary antibodies
diluted in 2.5% BSA (anti-GAPDH 1:4,000, anti-CYP1A2 1:1,000, and anti-CYP2E1 1:1,000)
overnight. Then membranes were incubated in an anti-rabbit IgG antibody (1:5,000) diluted in 2.5%
BSA. Protein bands were visualized using a ChemiDoc MP Imaging System (Bio-Rad, Hercules,
CA).

3.2.10 Statistical Analysis
The data are shown as mean ± SD (standard deviation). A two-tailed unpaired Student’s t test
was used to determine the significance of differences in lncRNA expression after shRNA
transfection. A two-way ANOVA followed by Tukey’s test was used to determine the significance
of differences in the MTT and LDH assays. A one-way ANOVA followed by Dunnett's test was
used to determine the significance of differences in the DHR123 staining and RT-PCR results.
Statistical analyses were performed using Prism7, version 7.01 from GraphPad Software, Inc. (La
Jolla, CA, USA). Differences were regarded as statistically significant if p<0.05.
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Table 3. 1 List of primers used for real time PCR.

SYBR Primers (Integrated DNA Technologies, Coralville, IA)
Gene
GAPDH
HNF1α-AS1
CYP1A2
CYP2E1
CYP3A4
SULT1A1
UGT1A1
UGT1A9
GSTP1
GSTT1

Primer Sequence
Forward 5′-GGGAGCCAAAAGGGTCAT-3′
Reverse 5′-GAGTCCTTCCACGATACCAA-3′
Forward 5′-TCAAGAAATGGTGGCTAT-3′
Reverse 5′-GCTCTGAGACTGGCTGAA-3’
Forward 5’-CCAACGTCATTGGTGCCATG-3’
Reverse 5’-GTGATGTCCCGGACACTGTTC-3’
Forward 5’-AATGGACCTACCTGGAAGGAC-3’
Reverse 5’-CCTCTGGATCCGGCTCTCATT-3’
Forward 5’-GATTGACTCTCAGAATTCAAAAGAAACTGA-3’
Reverse 5’-GGTGAGTGGCCAGTTCATACATAATG-3’
Forward 5’-AGGAGTTCATGGACCACAGC-3’
Reverse 5’-TGAAGGTGGTCTTCCAGTCC-3’
Forward 5’-CCTTGCCTCATCAGAATTCCTTC-3’
Reverse 5’-ATTGATCCCAAAGAGAAAACCAC-3’
Forward 5’-ATTCCCAGCTGCTTGCTCTC-3’
Reverse 5’-AAGCCTTGAACTCCCGGTC-3’
Forward 5’-TCCCCAGTGACTGTGTGTTG-3’
Reverse 5’-GAAGCCCCTTTCTTTGTTCA-3’
Forward 5’-TCACCTTGACGGAGAGTGTG-3’
Reverse 5’-CCAGGTACTCATCCACACGG-3’

TaqMan™ primer (Life Technologies, Carlsbad, CA)
Gene

Assay ID

GAPDH

Hs99999905_m1

HNF4α-AS1 Hs01378672_m1
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3.3 Results
3.3.1 Impact on APAP-induced Cytotoxicity by Knockdown of HNF1α-AS1 and HNF4αAS1
To study the roles of the lncRNAs, HNF1α-AS1 and HNF4α-AS1, in affecting the cytotoxicity
of APAP, HepaRG cells were stably transfected with shRNAs targeting these two lncRNAs as
well as a negative control. Several assays measuring APAP cytotoxicity, including MTT, LDH
release, and HDR123 staining assays were performed. Knockdown of HNF1α-AS1 and HNF4αAS1 by shRNA transfection in HepaRG cells yielded a decrease in their RNA levels to 0.41-fold
(95% confidence interval CI = 0.24 to 0.58, ***p<0.001) and 0.46-fold (CI = 0.23 to 0.71,
**p<0.01) comparing to their control groups (cells transfected with shNC), respectively, which is
indicative of successful knockdown (Figure 3.1A and 1B). Cells with stable lncRNA knockdown
were then treated with different concentrations of APAP for the assessment of cytotoxicity.
The MTT assay was performed to test cell viability after APAP challenge. Cells were treated
with different concentrations of APAP (0, 10, 30, or 100 mM) for 24 h. Cell viability was
normalized to the control group (cells transfected with shNC receiving no APAP treatment). As
shown in Figure 3.2A, knockdown of HNF1α-AS1 and HNF4α-AS1 did not alter cell viability in
non-APAP challenged cells. However, when treated with APAP at concentrations of 10 or 30 mM,
cells with lncRNAs knockdown showed a differential susceptibility to APAP toxicity. Specifically,
knockdown of HNF1α-AS1 led to increases in cell viability when treated with APAP at
concentrations of 10 or 30 mM, while the opposite was observed in HNF4α-AS1 knockdown cells,
where the cell viability was lower at the same APAP concentrations (Figure 3.2A). These results
indicate that these lncRNAs play opposing roles in the susceptibility to APAP-induced cytotoxicity.
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Figure 3. 1. Knockdown of lncRNAs HNF1α-AS1 and HNF4α-AS1 in HepaRG cells.
HepaRG cells during a growth period were stably transfected with a negative control shRNA
(shNC), shRNAs targeting HNF1α-AS1 (shHNF1α-AS1), or shRNAs targeting HNF4α-AS1
(shHNF4α-AS1). Relative expression of HNF1α-AS1 and HNF4α-AS1 was measured by RT-PCR.
The changes of relative mRNA expression compared to the shNC controls were calculated using
the 2-∆∆t method after normalization with GAPDH. Data are shown as mean ± SD (n = 3) and
analyzed by two-tailed unpaired Student’s t test. **p<0.01 and ***p<0.001 versus shNC controls.
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Figure 3. 2. Changes of APAP-induced cytotoxicity by knockdown of HNF1α-AS1 and HNF4αAS1 in HepaRG cells.
(A) Cell viability evaluated by the MTT assay after APAP treatment at concentrations of 0, 10, 30,
and 100 mM. (B) Cell damage assessed by the LDH release assay after APAP treatment. Data are
shown as mean ± SD (n = 3) and analyzed by a two-way ANOVA followed by Tukey’s test.
*p<0.05, **p<0.01, and ***p<0.001 versus shNC controls receiving different concentrations of
APAP.
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At 100 mM APAP, which is a highly toxic concentration, no differences in cytotoxicity were
observed and cell viability was low among all three groups of HepaRG cells.
The LDH release assay was used for detecting extent of cell damage. Aside from cell death,
damage of living cells was another parameter to assess drug-induced cytotoxicity. As expected,
Figure 3.2B shows no increases in LDH release after knockdown of HNF1α-AS1 and HNF4αAS1 when not challenged with APAP. Increases in LDH release were observed in HNF4α-AS1
knockdown cells treated with 10 or 30 mM APAP. By contrast, HNF1α-AS1 knockdown cells
treated with the same concentrations of APAP had lower LDH values in comparison to shNC cells.
Similar to the results of the MTT assay, no differences in LDH release values were observed at
100 mM APAP in all three groups of HepaRG cells.
Overproduction and accumulation of reactive oxygen species (ROS) and induction of oxidative
stress is one of the main features for AILI. Figure 3.3 shows the analysis of ROS production by
DHR123 staining. Under normal conditions, no fluorescence was detected in any of the groups of
cells (data not shown). However, with APAP treatment, differences in fluorescent intensity were
observed. Positive stained cells, indicative of ROS accumulation, were observed in all three groups
of cells exposed to 10 mM APAP (Figure 3.3A). Quantification results (Figure 3.3B) showed that
cells with HNF4α-AS1 knockdown had 1.64-fold (CI =1.36 to 2.02, **p<0.01) higher fluorescent
intensity comparing to the control group (cells transfected with shNC receiving 10 mM APAP
treatment), while cells with HNF1α-AS1 knockdown led to a 0.47-fold (CI =0.36 to 0.59, *p<0.05)
lower fluorescent intensity. Notably, only metabolically active hepatocyte-like cells, which
express CYP enzymes, were stained positively by DHR123, while no fluorescence was detected
in cholangiocyte-like cells in the cultures of HepaRG cells.
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This observation indicates that the production of ROS co-localizes to cells where CYPmediated bioactivation of APAP occurs. The cells with HNF4α-AS1 knockdown showed an
observable brighter green fluorescence compared to other groups, indicating higher levels of ROS,
which is consistent with higher toxicity in those cells. By contrast, fewer positive stained cells and
dimmed green fluorescence were detected in HNF1α-AS1 knockdown cells, indicating lower
levels of ROS, which is also in agreement with the higher tolerance of these cells to APAP.
The results from the cytotoxicity assays performed here provided strong evidence that
knockdown of lncRNA HNF1α-AS1 or HNF4α-AS1 altered cell susceptibility to APAP
cytotoxicity. The absence of HNF4α-AS1 increased susceptibility to APAP-induced cytotoxicity,
while deletion of HNF1α-AS1 afforded tolerance to APAP cytotoxicity.
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Figure 3. 3. Changes of APAP-induced cytotoxicity viewed by DHR123 staining in HepaRG cells
with knockdown of lncRNAs HNF1α-AS1 and HNF4α-AS1.
(A) Quantification of fluorescent intensity in different group of cells after treated with 10 mM
APAP. (B) The representative images are shown with green fluorescence in hepatocyte-liver cells.
Bar = 200 µM. Data are shown as mean ± SD and analyzed by a one-way ANOVA analysis
followed by Dunnett's test. *p<0.05, **p<0.01, and ***p<0.001 versus the shNC controls
receiving 10 mM APAP.

108

3.3.2 Impact on Metabolic Pathways of APAP by Knockdown of HNF4α-AS1 and
HNF1α-AS1
To determine how knockdown of HNF1α-AS1 and HNF4α-AS1 affects APAP-induced
cytotoxicity, the enzymes involved in the metabolic pathways of APAP were examined. As shown
in Figure 3.4, APAP is metabolized by several phase I and II enzymes, whose combined functions
ultimately determine cytotoxicity outcome. NAPQI, the toxic metabolite, is produced by CYPmediated bioactivation of APAP. The major CYPs involved in this process are CYP1A2, 2E1, and
3A4. Several phase II enzymes, including SULT1A1, UGT1A1, and 1A9, are also able to
biotransform APAP, forming non-toxic APAP-conjugates. Furthermore, NAPQI can be detoxified
by reacting with cellular glutathione, mediated by GSTP1 and GSTT1. The mRNA levels of these
genes were measured in HNF4α-AS1 and HNF1α-AS1 knockdown as well as control shNC
HepaRG cells. As shown in Figure 3.5A, knockdown of HNF1α-AS1 and HNF4α-AS1 affected
the mRNA levels of all selected APAP-metabolizing CYP genes. Knockdown of HNF1α-AS1
repressed mRNA levels of all CYP genes examined. Specifically, HNF1α-AS1 knockdown
repressed mRNA levels of CYP1A2 to 0.71-fold (CI = 0.61 to 0.81, *p>0.05), CYP2E1 to 0.35fold (CI = 0.31 to 0.39, **p<0.01), and CYP3A4 to 0.31-fold (CI = 0.0052 to 0.61, *p<0.05)
comparing to the control group (cells transfected with shNC). By contrast, knockdown of HNF4αAS1 induced mRNA levels of CYP1A2 by 1.3-fold (CI = 0.38 to 2.22, p>0.05), CYP2E1 by 1.95fold (CI = 1.27 to 2.63, ***p<0.001), and CYP3A4 by 1.9-fold (CI = 1.00 to 2.81, **p<0.01)
comparing to the control group. These changes were further confirmed by analysis of protein
abundance by Western blots. As shown in Figure 3.5B, the pattern of protein-level changes for
CYPs is similar to that of mRNA expression. Collectively, these data indicate that lncRNAs
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HNF1α-AS1 and HNF4α-AS1 are involved in the regulation of functional activity of
biotransformation pathways for APAP, ultimately impacting APAP-induced cytotoxicity.
HNF4α-AS1 knockdown produced no changes in mRNA levels of selected phase II enzymes,
including SULT1A1, UGT1A1, and 1A9 (Figure 3.6A). The mRNA levels of SULT1A1 and
UGT1A9 was decreased by knockdown of HNF1α-AS1 to 0.64-fold (CI = 0.48 to 0.80, *p<0.05)
and 0.72-fold (CI = 0.59 to 0.85, *p<0.05) comparing to the control group, respectively, while no
changes in the mRNA level of UGT1A1 was found. For GSTs, the mRNA levels of GSTT1 were
comparable among all three groups of cells. Even though the decreases in mRNA levels of GSTP1
by knockdown of both HNF1α-AS1 and HNF4α-AS1 were detected (Figure 3.6B), considering
the expression level of GSTP1 in HepaRG cells is very low (Cq value around 35, data not shown),
these changes were not believed to cause major changes in APAP metabolism and cytotoxicity.
Taken together, these results indicate that the changes in mRNA and protein levels of CYP
enzymes by knockdown of HNF1α-AS1 and HNF4α-AS1 are the most likely mechanisms for the
differential susceptibility to APAP-induced cytotoxicity in HepaRG cells.
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Figure 3. 4. Metabolic pathways of APAP in liver by phase I and II enzymes.
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Figure 3. 5. Impact on expression of APAP-metabolizing phase I enzymes in HepaRG cells with
knockdown of HNF1α-AS1 and HNF4α-AS1.
(A) Relative mRNA expression of CYP1A2, 2E1, and 3A4 was measured by RT-PCR. The
changes of relative mRNA expression compared to the shNC controls were calculated using the 2∆∆t

method after normalization with GAPDH. Data are shown as mean ± SD (n = 3) and analyzed

by a one-way ANOVA analysis followed by Dunnett's test. Three separate one-way ANONAs
were run. *p<0.05, **p<0.01, and ***p<0.001 versus the shNC controls. (B) Protein expression
of CYP1A2 and 2E1 was determined by Western blots. GAPDH was used as an internal control.
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Figure 3. 6. Impact on expression of APAP-metabolizing phase II enzymes in HepaRG cells with
knockdown of HNF1α-AS1 and HNF4α-AS1.
(A) Relative mRNA expression of SULT1A1, UGT1A1, and 1A9 was measured by RT-PCR.
(B) Relative mRNA expression of GSTP1 and GSTT1 was measured by RT-PCR. The changes
of relative mRNA expression compared to the shNC controls were calculated using the 2-∆∆t
method after normalization with GAPDH. Data are shown as mean ± SD (n = 3) and analyzed by
a one-way ANOVA analysis followed by Dunnett's test. Three ANOVAs for the top panel; two
for the bottom panel. *p<0.05, **p<0.01, and ***p<0.001 versus shNC controls.
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3.4 Discussion
Regulation of transcription factors including HNF1α and HNF4α, either by gene edition
techniques or endogenous miRNAs, has been reported to affect cellular response to APAP-induced
cytotoxicity [250-252]. The current study also proves that the neighborhood antisense lncRNAs
HNF1α-AS1 and HNF4α-AS1 also affect APAP-induced cytotoxicity independently. The
manipulation of expression of HNF1α-AS1 and HNF4α-AS1 alone is unable to affect expression
of HNF1α and HNF4α as described in our previous studies [246,253], but is able to alter the mRNA
and protein levels of APAP-metabolizing CYP enzymes and downstream APAP-induced
cytotoxicity in HepaRG cells. These results suggest several critical features of the lncRNAs in the
regulation of CYP expression and functions. Firstly, these lncRNAs work as downstream factors
to regulate the CYPs together with the transcription factors of HNF1α and HNF4α. Indeed, several
studies have suggested that the RNA levels of lncRNAs HNF1α-AS1 and HNF4α-AS1 are
controlled by HNF1α and HNF4α [169,246,247]. In addition to directly binding to the CYP genes,
the transcription factors HNF1α and HNF4α may also regulate CYP expression indirectly through
their neighborhood lncRNAs. Secondly, the lncRNAs have distinct functions in the regulation of
their target genes. As showed here and in our previous studies, knockdown of HNF1α-AS1 and
HNF4α-AS1 generated opposing effects on the expression of several CYPs at both the mRNA and
protein levels, which correlated well with contrasting effects on APAP-induced cytotoxicity. This
phenomenon indicates that the lncRNAs HNF1α-AS1 and HNF4α-AS1 may be involved in a
dynamic interrelated regulation of CYPs, where both upregulation and downregulation can occur.
Generally, the binding of transcription factors to their target genes promotes gene expression,
leading to upregulation of gene expression, which is the case for induction of some CYPs by
activation of the pregnane X receptor (PXR) or constitutive androstane receptor (CAR) [254].
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However, how altered expression of CYPs returns to normal basal levels and whether negative
feedback loops contribute to the regulation of CYP genes remain largely unknown. The roles of
lncRNAs HNF1α-AS1 and HNF4α-AS1, which have opposing effects on the regulation of CYP
expression in controlling CYP functions under different physiological conditions, need to be
addressed in future studies. Activation of some nuclear receptors, such as PXR and CAR, has been
reported to affect AILI [255,256]. Expression of PXR or CAR can also been affected by alterations
of lncRNAs HNF1α-AS1 or HNF4α-AS1 [246]. These lncRNAs may regulate expression of CYPs
and affect susceptibility to AILI through indirect alterations of PXR or CAR, but this assumption
needs to be confirmed in a future study.
LncRNAs need cofactors to perform their functions in gene regulation. Studies have shown
that lncRNAs are able to interact with other molecules, such as DNA, RNA, and proteins, to
perform functions as signaling, decoys, guides, and scaffolds [94]. Identifying what molecules are
able to interact with lncRNAs is a critical step to understand how lncRNAs perform their
regulatory functions. One study has showed that HNF1α-AS1 is able to directly interact with
miRNA and regulates proliferation and invasion of non-small cell lung cancer (NSCLC) cells
[172]. LncRNA HNF1αOS1, a neighborhood antisense lncRNA of mouse Hnf1α gene, has been
shown to interact with enhancer of zeste homolog 2 (EZH2) in mouse liver by RNA
immunoprecipitation sequencing [257]. EZH2 is a catalytic subunit of the polycomb repressive
complex 2, which mediates the formation of tri-methylation at histone H3 lysine 27 [258,259].
This evidence suggests that lncRNAs HNF1α-AS1 and HNF4α-AS1 may regulate CYP expression
through multiple mechanisms by interacting with different types of molecules. Identification of
molecules, mainly miRNAs or proteins, binding to HNF1α-AS1 and HNF4α-AS1, is one of our
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current research interests to uncover the molecular mechanisms of HNF1α-AS1- and HNF4α-AS1mediated regulation of CYP expression.
LncRNAs should be considered as novel factors predicting drug metabolism and cytotoxicity.
By generating loss-of-function cell models, the current study has suggested that expression of
lncRNAs HNF1α-AS1 and HNF4α-AS1 is important for APAP-induced cytotoxicity. Notably, in
the correlation study performed by Wang and her colleagues using human liver samples, results
do not only show that expression levels of HNF1α-AS1 are positively correlated to several CYPs,
but also pointed out that HNF1α-AS1 is expressed at different levels among individuals [247].
Besides the well-known factors that regulate CYP-mediated drug metabolism, which have been
shown to impact clinical outcomes of drug treatment, expression and function of CYP-regulating
lncRNAs should be also counted as an additional factor [17,239].
Multiple mechanisms are able to regulate the expression of lncRNAs. The NCBI database of
human single nucleotide polymorphisms (SNPs) has listed thousands of SNPs existing in the
HNF1α-AS1 and HNF4α-AS1 genes (https://www.ncbi.nlm.nih.gov/snp/), which might be
responsible for the inter-individual variations in the expression of these lncRNAs. Multiple studies
have suggested that lncRNAs are differentially expressed under disease conditions, including
cancer, which also suggest that lncRNAs can be affected and expressed differently for a same
individual at different times or conditions [260]. However, no studies have been performed to
determine how SNPs in these genes affect expression or function of HNF1α-AS1 and HNF4α-AS1
or their downstream-regulated genes. More future studies are urgently needed to address these
knowledge gaps in their clinical relevance for drug metabolism and cytotoxicity.
In the current research project, HepaRG was used as an experimental model to study the roles
of lncRNA in AILI. The hepatoma derived HepaRG cell line has been widely used as a new in
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vitro model in the study of liver functions due to its high expression levels of drug metabolizing
enzymes and transporters [214,261]. However, several limitations still exist in HepaRG cell model.
The differentiated HepaRG cells are composed of both hepatocyte-like cells, which act similar to
primary hepatocytes, and cholangiocyte-like cells, which act similar to epithelial cells and do not
respond to APAP treatment. When harvesting samples from differentiated HepaRG cells, it is
difficult to separate these two types of cells, which will ultimately affect the experimental
outcomes. Secondary, several SNPs have been identified in HepaRG cells, including CYP2D6,
OATP1B1, and MRP2 genes, which may lead to dysfunctions of these proteins. The human
primary hepatocytes, which is regarded as the “gold standard model” for in vitro metabolism and
toxicity studies will be used in the future to validate our findings in HepaRG cells.
In conclusion, the present study demonstrates that lncRNAs HNF1α-AS1 and HNF4α-AS1 are
able to alter APAP-induced cytotoxicity in HepaRG cells with opposite effects, primarily by
affecting expression of the CYP enzymes (Figure 3.7).
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Figure 3. 7. Mechanistic summary of HNF1α-AS1 and HNF4α-AS1 in susceptibility of AILI.
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Chapter 4. LncRNA in P450 induction by rifampicin

4.1 Introduction
One of the special characteristics for some P450 enzymes, but not all P450s, this that their
expression can be induced under some circumstances, including drug treatment [262]. This
phenomenon is believed to be a dose-dependent adaptive response of the drug-metabolizing
system, which is likely to be evolved to protect against the accumulation of xenobiotics or toxicants
[199]. Induction of P450s usually leads to increased detoxification of xenobiotics, but it also might
lead to the formation of active or toxic metabolites occasionally.
One major concern of P450 induction is that it might lead to drug-drug interactions (DDIs). By
definition, DDIs refer to the phenomenon where the administration of one drug alters the
therapeutic efficacy or adverse effects of another drug taken concurrently. DDIs might lead to
significant variations in the drug response or toxicity in patients who are taking several drugs
simultaneously. However, with the prevalence of chronic diseases, there is an increasing number
of patients who are on polypharmacy, where multiple drugs are given to treat various diseases
[263]. Drugs, which can induce the expression of certain P450s via the upregulation of gene
transcription activity, may affect the metabolism of the substrate by the induced P450s. If a second
drug, or called a victim drug, is administrated at the same time with the P450 inducer drug, DDI
is likely to happen, leading to an alteration in the efficacy or toxicity of the victim drug. There is
an increase of evidence showing that P450 inducing drugs and DDIs have critical impacts on the
therapeutic effect and safety of clinical drug usages [264].
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Rifampicin (RIF) is an antibiotic, which is widely used in the treatment of gram-positive
bacteria, including mycobacteria. RIF is also used in combination with other drugs, including
isoniazid, pyrazinamide, and streptomycin, in the treatment of tuberculosis [265,266]. Back in
1972, RIF was first identified as a P450 inducer [267]. This effect of RIF was later found to affect
the clearance of several other therapeutic agents, for example, the use of RIF at 600 mg/day was
reported to cause a 3-fold increase in the clearance of propranolol [268]. In later studies, RIF was
found to induce the expression of several P450 isoforms, including CYP1A2, 2C9, 2C19, and
3A4 [269]. Nowadays, RIF related DDIs and models to predict DDIs have been reported and
summarized to help the improvement of safety in clinical practice [270-272].
The molecular mechanism in RIF-mediated P450 induction is better understood now. RIF was
identified as a ligand for transcription factor PXR. PXR was a key transcription factor, which could
activate several hepatic genes involved in drug metabolism [273]. Upon activation, PXR activates
the transcription of several P450s by binding to the response element in the promoter region
[194,274]. PXR was reported to be important for the induction of CYP3A4, a P450 isoform
responsible for almost one-third of clinically used drugs. One study using Pxr null mice showed
that the expression of CYP3A11, mouse P450 relevant to human CYP3A4, was dysregulated,
indicating an important role of PXR in CYP3A11 activation [275].
The mechanisms of how PXR activates CYP3A4 have not been fully understood yet. Recent
studies have demonstrated that PXR was able to bind directly to the CYP3A4 promoter and two
PXR response elements (distant and proximal) have been identified in the promoter region of
CYP3A4 gene. However, the molecular activities after PXR binding are still not clear. Several
cofactors have been identified in the PXR mediated transcription activation of P450s [276].
Transcription factors including FOXO, HNF1α, HNF4α, and SHP have been shown to involve in
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the CYP3A4 activation by PXR [202,277-279]. Other than transcription factors, epigenetic
modifying enzymes were also reported to involve in the process of PXR mediated CYP3A4
induction. Yan et al. identified that epigenetic modifications might involve in this process. They
found that RIF treatment led to increased levels of H3K4me3, H3 acetylation, and decreased levels
of H3K27me3 in the promoter region of CYP3A4. Knockdown of PXR not only repressed the
induction of CYP3A4 by RIF, but also abolished the changes in histone modifications [23].
Another study also showed that protein arginine methyltransferase 1, a histone tail
methyltransferase, was important for the transcriptional activation of CYP3A4 by PXR [280]. All
these studies suggested that cofactors are critical players in transcription activation by transcription
factors.
However, no studies have studied whether lncRNAs are also involved in the drug induction of
P450s by serving as cofactors. As we already established that lncRNAs were involved in basal
expression of P450s and transcription factors, we hypothesize that lncRNAs are also involved in
drug-induced expression of P450s. In this study, we used RIF as a model drug and tested how
lncRNAs responded to drug treatment.

122

4.2 Materials and Methods

4.2.1 Chemicals and Reagents
HepaRG cells were kindly provided by Biopredic International (Rennes, France). ADD710
growth additives and ADD720 differentiation additives were purchased from Biopredic
International. William’s E Media (WEM), collagen I coated T-25 flasks, collagen I coated 12well plates, Glutamax™ Supplement, and Opti-MEM medium were obtained from Thermo
Fisher Scientific (Carlsbad, CA). RIF was purchased from Sigma-Aldrich (St. Louis, MO).

4.2.2 Cell Culture
HepaRG cells were cultured following a protocol from Biopredic International. Briefly, a
three-step protocol was used to generate fully differentiated HepaRG cells. Cells were first thawed
and cultured in HepaRG growth medium (William’s E Media supplied with Glutamax™ and
ADD710 growth additives) for two weeks in order to reach full confluence. Cells were next
cultured in a 1:1 mixture of HepaRG growth medium and a HepaRG differentiation medium
(William’s E Media supplied with Glutamax™ and ADD720 growth additives) for one week. In
the last step, cells were cultured in HepaRG differentiation medium for another week to reach a
full differentiation status. During the whole process, cells were incubated at 37°C and 5% CO 2
with the medium changed every 3 days. Fully differentiated cells were either used directly in T-25
flash or trypsinized and seeded into collagen I coated 12-well plates for further treatment.

123

4.2.3 Drug Treatment
For drug treatment, differentiated HepaRG cells were treated with 50 µM RIF, or vehicle (0.1%
DMSO) for 24 hours. After drug treatment, cells were harvested at different time points and RNAs
were isolated for analysis of gene expression.

4.2.4 RNA Isolation and Quantitative Real-Time PCR (RT-PCR)
Total RNAs were isolated from HepaRG cells using a TRIzol™ reagent according to the
manufacturer’s protocol. RNA concentration was measured by a Nano Drop spectrophotometer
(Nano Drop Technologies, Wilmington, DE) at 260 nm and RNA integrity was evaluated using an
Agilent 2200 Tape Station (Agilent Technologies, Santa Clara, CA). One µg of total RNAs was
subjected to cDNA synthesis using an iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories,
Hercules, CA). Real-time PCR was performed using a CFX96™ Real-Time System (Bio-Rad
Laboratories, Hercules, CA) with the primer sequences described in previous sections. Expression
of GAPDH, HNF1α, PXR, HNF1α -AS1, and CYP3A4 were measured using an iTaq™ Universal
SYBR® Green Supermix (Bio-Rad Laboratories, Hercules, CA). Relative mRNA expression
levels were determined by normalizing examined gene expression against GAPDH expression
using ΔΔCt method.

4.2.5 Statistical Analysis
The data are shown as mean ± SD (standard deviation). The significance of differences
between means was determined using a two-tailed unpaired Student’s t test. Statistical analyses
were performed using Prism7, version 7.01 from GraphPad Software, Inc. (La Jolla, CA, USA).
Differences were regarded as statistically significant if p < 0.05.
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4.3 Results

4.3.1 Alteration of PXR and CYP3A4 by Rifampicin treatment in HepaRG cells
To study the alterations in the expression of PXR and CYP3A4 following RIF treatment,
HepaRG cells were treated with 50 μM of RIF for 24 hours. Cells were harvested at 48 hours, 96
hours, and 144 hours after treatment, which was 72 hours, 120 hours, and 168 hours after
experiment start in the figures. Expression of PXR and CYP3A4 was measured by RT-PCR at
each of the time points mentioned above.
The expression pattern of PXR was shown in Figure 4.1A. Interestingly, the expression of
PXR remained largely unchanged after RIF treatment for 24 hours. However, an increase in the
expression of PXR was observed at 48, 96, and 144 hours after treatment, with 2.4-, 3-, and 2.2fold induction, respectively.
As shown in Figure 4.1B, the expression of CYP3A4 was induced by 2.5-fold after 24 hours
of RIF treatment. Forty-eight hours after treatment, CYP3A4 reached peak expression level in all
tested time points, with an 8.3-fold induction comparing to cells treated with vehicle. The
expression level of CYP3A4 dropped to 4.7- and 4-fold induction at 96 and 144 hours after
treatment, respectively. These results suggested that RIF treatment was able to induce the
expression of PXR and CYP3A4 in HepaRG cells, and the induction levels changed with time.
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Figure 4. 1. Expression of PXR and CYP3A4 after RIF treatment
(A) Alteration in expression of PXR by RIF treatment in HepaRG cells. (B) Induction of CYP3A4
by RIF treatment in HepaRG cells. The sample size for each group is n = 3. Data are shown as
mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control in two-tailed unpaired Student’s
t tests.
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4.3.2 Alteration of HNF1α and HNF1α-AS1 by RIF treatment in HepaRG cells
The expression of HNF1α and its neighborhood lncRNA HNF1α-AS1 was also measured in
HepaRG cells treated with RIF.
As shown in Figure 4.2A, the expression HNF1α remained largely unchanged with only a 1.4fold increase 48 hours after RIF treatment, which returned to normal in the next time point.
For HNF1α-AS1, RIF treatment also did not induce its expression right after 24 hours.
However, the expression of HNF1α-AS1 was induced for 2-fold at 48 hours after treatment and
this induction remained in the later time points (Figure 4.2B).
These results indicated that RIF treatment was able to induce the expression of HNF1α-AS1
but has limited effects on the expression of HNF1α.

4.3.3 Correlation between HNF1α-AS1 and CYP3A4 in RIF treated HepaRG cells
To study the relationship between the expression of HNF1α-AS1 and CYP3A4 after RIF
treatment, the correlation coefficient was calculated. A correlation coefficient of +0.85 was
calculated between the relative expression of HNF1α-AS1 and CYP3A4, indicating the existence
of a strong positive correlation between HNF1α-AS1 and CYP3A4 after RIF treatment.
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Figure 4. 2. Expression of HNF1α and HNF1α-AS1 after RIF treatment
(A) Alteration in expression of HNF1α by RIF treatment in HepaRG cells. (B) Alteration in
expression of HNF1α-AS1 by RIF treatment in HepaRG cells. The sample size for each group is
n = 3. Data are shown as mean ± SD. *p < 0.05 and **p < 0.01 versus control in two-tailed unpaired
Student’s t tests.
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4.4 Discussion
Drug mediated P450 induction is a common cause for DDI in clinical practice. Even this
phenomenon has been reported for over four decades, the underlying molecular mechanism is still
not fully explained yet. The identification of “xenobiotic sensor” transcription factors made a great
progress in understanding the mechanisms in P450 induction. PXR, as one of the “xenobiotic
sensor”, has been identified to induce the expression of CYP3A4 when stimulated by RIF [281].
Knockdown of PXR in HepaRG cells resulted in abolished induction after RIF treatment,
indicating that PXR is the major mediator in the induction of CYP3A4 by RIF treatment [282].
PXR was reported to mediate the transcription activation by binding to the response elements in
the promoter region of CYP3A4. However, what molecular changes happen after PXR binding is
still under investigation.
In recent studies, several cofactors, including other transcription factors and epigenetic
modifying enzymes, have been identified to play critical roles after PXR binding to CYP3A4 and
mediate the transcription activation of CYP3A4 [23,279]. These studies suggest the existence of a
complex regulatory mechanism between the processes of PXR binding and CYP3A4 induction.
In the current study, we studied how RIF treatment altered gene expression in HepaRG cells
at different time points. The induction of CYP3A4 was observed at all tested time points with
different levels of induction. The highest induction level was found at 48 hours after RIF treatment
and the induction of CYP3A4 persisted 120 hours after RIF treatment. The levels of CYP3A4
started to drop after 48 hours, indicating that the induction was a relatively reversible process. One
study reported that the treatment of pregnenolone 16α-carbonitrile, a mouse PXR activator, in the
early age of mice led to persistently induction ofCYP3A11 through alteration of histone
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modifications in the PXR response elements of the Cyp3a11 promoter [283], indicating that PXR
activation might lead to permanent regulation to its target genes. However, how the histone
memory of CYP3A4 changed and whether the expression of CYP3A4 will resume to a normal
level is not known in RIF treated HepaRG cells. Future studies with a longer observation time and
experiments investigating the histone signature of CYP3A4 would be recommended to answer
these questions.
LncRNAs have been recently found to involve in almost every step of gene regulation. In our
previous studies, we identified that lncRNA HNF1α-AS1, a neighborhood lncRNA to transcription
factor HNF1α, was able to regulate the expression of several P450s and transcription factors.
However, whether lncRNAs also involved in the induction of CYP3A4 upon PXR activation by
RIF has not been studied yet. In the current study, we observed that expression of HNF1α-AS1
was also induced by RIF treatment. Interestingly, the coding gene HNF1α also showed a mild
induction 48 hours after RIF treatment, at which point the HNF1α-AS1 also showed the highest
expression. HNF1α-AS1 has been reported to be regulated by HNF1α [284]. In this case, the
upregulation of HNF1α-AS1 might have resulted from HNF1α induction. The expression of PXR
was also found to be upregulated after RIF treatment. Whether this upregulation of PXR is
mediated by HNF1α-AS1 is not known. Further, a positive correlation between HNF1α-AS1 and
CYP3A4 was observed, which also indicated that HNF1α-AS1 might involve in the induction of
CYP3A4. However, to really investigate whether lncRNA HNF1α-AS1 is a critical factor in the
PXR mediated induction of CYP3A4, a loss-of-function model is still needed.
In summary, in the current part of the study, we found that RIF was able to induce the
expression of CYP3A4, HNF1α-AS1, HNF1α, and PXR. However, how these factors work
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together is still not clear and future studies using HNF1α-AS1 knockdown model are needed to
address these questions.
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Chapter 5. Summary and Future Directions
The studies discussed in this dissertation fill in a knowledge gap by identifying lncRNAs
involved in xenobiotic metabolism by regulating hepatic P450s. In the current study, two
transcription factor neighborhood lncRNAs, HNF1α-AS1 and HNF4α-AS1, were functionally
characterized. In order to study the functions of HNF1α-AS1 and HNF4α-AS1, lncRNA loss-offunction models were generated using siRNA and shRNA transfection into HepaRG cells. In the
first set of experiments (Chapter 2), we found the expression of P450s in HepaRG cells was
regulated by a network composed of transcription factors and lncRNAs. Knockdown of HNF1αAS1 or HNF4α-AS1 affected the expression of several P450s and P450 regulatory transcription
factors, including PXR and CAR, in HepaRG cells. The effects of lncRNA knockdown to P450
expression were found to be opposite between HNF1α-AS1 and HNF4α-AS1 knockdown.
Knockdown of HNF1α-AS1 led to P450 repression, while knockdown of HNF4α-AS1 resulted in
upregulation of P450s. Furthermore, the expression of HNF1α-AS1 and HNF4α-AS1 was depleted
by knocking down of their neighborhood coding gene encoded proteins, HNF1α and HNF4α,
respectively, indicating that the lncRNAs were regulated by their neighborhood coding gene
encoded proteins. The major finding of Chapter 2 is that lncRNAs are involved in transcription
regulation of P450s in HepaRG cells.
In the next part of the study (Chapter 3), we further investigated whether knockdown of
HNF1α-AS1 or HNF4α-AS1 also affected P450 mediated drug biotransformation and drug
toxicity. Using APAP as a model drug, we found that HNF1α-AS1 or HNF4α-AS1 knockdown
changed the susceptibility of HepaRG cells to APAP, also in the opposite way. As showed by
several toxicity and cell viability assays, HNF1α-AS1 knockdown decreased APAP induced
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cytotoxicity, while HNF4α-AS1 knockdown exacerbated APAP induced cytotoxicity. The
analysis of excretion alteration to Phase I and II enzymes involved in APAP biotransformation
showed that P450 alteration, in both mRNA and protein levels, by lncRNA knockdown is the
major cause of differential responses to APAP. The conclusion for this study is that lncRNAs were
able to affect drug metabolism process and drug toxicity by affecting P450 expression and function.
In Chapter 4, HNF1α-AS1 was found to respond to RIF treatment in HepaRG cells, indicating
that lncRNAs might also involve in P450 induction by drug treatment.
The current studies are just a good start in understanding lncRNAs in the field of drug
metabolism. Many questions still exist and remain to be addressed in future studies: 1) Which is
the primary target of HNF1α-AS1 and HNF4α-AS1, P450 genes, or transcription factors; 2) Are
the functions of HNF1α-AS1 and HNF4α-AS1 depend on HNF1α and HNF4α or the two lncRNAs
can function independently of their neighborhood coding genes; 3) Whether HNF1α-AS1 and
HNF4α-AS1 affect characteristics of P450 genes and related transcription factor, such as
epigenetic markers.
Before answering these questions, one fundamental question needs to be addressed: what are
interacting molecules to HNF1α-AS1 and HNF4α-AS1. According to previous research, HNF1αAS1 has been reported to interact with both miRNAs and proteins to regulate cellular functions in
several cancer cells. In this case, it is rational to hypothesize that HNF1α-AS1 and HNF4α-AS1
also perform their P450 regulatory functions by interacting with miRNAs and proteins.
Several miRNAs were predicted to interact with HNF1α-AS1 and HNF4α-AS1 using ENCORI
program, an online database focusing on miRNA-target interactions. Among these miRNAs, some
were reported to involve in P450 expression [285]. Validation of these predicted miRNA-lncRNA
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interactions would be a good start to study whether miRNA sponge is one mechanism in P450
regulation by HNF1α-AS1 and HNF4α-AS1. To analyze lncRNA-Protein interactions, RNAProtein pull-down assays and RNA immunoprecipitation (RIP) are widely used [286].
Identification and characterization of the HNF1α-AS1 and HNF4α-AS1 interacting proteins will
give hints about whether HNF1α-AS1 and HNF4α-AS1 can function as protein decoys or scaffolds.
A better model is also needed in the future studies. While the current described studies are
performed in cell based in vitro models, an in vivo model will be much better in mimicking human
conditions. In the mouse genome, mouse Hnf1α and Hnf4α genes are also companioned by two
lncRNA genes, named Hnf1αos1 and Hnf4αos1. Based on the results of sequence alignment,
mouse Hnf1αos1 and Hnf4αos1 can be considered as homolog lncRNAs to human HNF1α-AS1
and HNF4α-AS1. However, very limited studies have been done regarding these two mouse
lncRNAs. We have tried to knockdown Hnf1αos1 by injection adeno-associated virus containing
shRNAs targeting Hnf1αos1. However, the knockdown efficiency is very limited. Other geneediting methods, such as CRISPR-Cas9 system, could serve as an alternative way to knockdown
these lncRNAs in mouse liver. Another model is the humanized liver mouse model, which was
reported to have human-like metabolic responses to drugs [287].
The goal of the current research is to understand how HNF1α-AS1 and HNF4α-AS1 affect the
metabolic function in humans. The generated knowledge could help to improve drug efficacy and
safety in clinical usages. However, several barriers still exist to achieve this.
First, to what extent can these two lncRNAs affect liver function in humans or drug metabolism
in clinical drug uses remains to be determined. In the current study, most of the results were
generated using a loss-of-function in vitro model. However, this model has limitations in
representing the actual expression variations of HNF1α-AS1 or HNF4α-AS1 in the population, as
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well as the actual effects of lncRNA to P450 function. Second, the significances of lncRNAs are
still ignored in clinical practice. Comparing to variations or mutations to coding genes, the patients’
noncoding gene signatures are generally not tested or recorded. Variations of lncRNAs are also
not taken into consideration when giving prescriptions or generating treatment strategies.
To overcome these barriers, several future studies need to be performed. In the first place, how
the levels of HNF1α-AS1 or HNF4α-AS1 are distributed in the population should be measured.
Getting to know the extent of interindividual variances of HNF1α-AS1 and HNF4α-AS1 is critical
to predict whether these two lncRNAs have significant impacts on hepatic function. In the
following step, studies should be performed to collect data regarding the correlations between
HNF1α-AS1/ HNF4α-AS1 levels in humans and their hepatic functions, activities of specific P450
isoforms, and drug responses. With an increasing number of studies showing the importance of
lncRNA to human health, more attention should be put on how lncRNAs affect clinical outcomes
in drug efficacy and toxicity.
Finally, HNF1α-AS1 and HNF4α-AS1 are potential drug targets for future drug designs.
HNF1α-AS1 and HNF4α-AS1 have been found to highly involved in physiological and
pathological activities in humans, making them great potential targets to treat diseases [288,289].
Conventional drugs and the recently developed siRNA-based drugs targeting HNF1α-AS1 and
HNF4α-AS1, or other lncRNAs with potential therapeutic benefits might be novel treatment
strategies for human diseases in the future [290].
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